{"questions": [{"id": "6402c910201352f04a00000c", "type": "yesno", "body": "Can losartan reduce brain atrophy in Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19416949", "http://www.ncbi.nlm.nih.gov/pubmed/21512418", "http://www.ncbi.nlm.nih.gov/pubmed/33150361", "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "http://www.ncbi.nlm.nih.gov/pubmed/31219516", "http://www.ncbi.nlm.nih.gov/pubmed/31026619", "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "http://www.ncbi.nlm.nih.gov/pubmed/21174483", "http://www.ncbi.nlm.nih.gov/pubmed/34948942"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/21174483", "text": "Since the hippocampus is a plastic structure and atrophy of this structure is closely related to the pathophysiology of Alzheimer's disease, if we could control blood pressure, regulate blood sugar, treat behavioural and psychological symptoms, achieve satisfactory lipid lowering and maintain a seizure-free state in patients with Alzheimer's disease, this may not only improve disease control but could also potentially affect the rate of disease progression.", "offsetInBeginSection": 3430, "offsetInEndSection": 3640, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19416949", "text": " Our results suggest that imaging-based spatial patterns of brain atrophy of Alzheimer's disease, evaluated with sophisticated pattern analysis and recognition methods, may be useful in discriminating among CN individuals who are likely to be stable versus those who will show cognitive decline", "offsetInBeginSection": 1767, "offsetInEndSection": 2061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34948942", "text": "for Alzheimer's prevention. Even so, research has shown that we can take steps to reduce the risk of developing it. Prospective studies have found tha", "offsetInBeginSection": 1325, "offsetInEndSection": 1475, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31135048", "text": "Medial temporal sparing in non-amnestic Alzheimer's disease may thus be due in part to later onset of medial temporal degeneration than in amnestic patients rather than different rates of atrophy over time.", "offsetInBeginSection": 2293, "offsetInEndSection": 2449, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "text": "We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could reduce brain volume loss, as a measure of disease progression, in clinically diagnosed mild-to-moderate Alzheimer's disease.", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33150361", "text": "The results suggest that TDP-43 and tau have different contributions to acceleration and deceleration of brain atrophy rates over time in both Alzheimer's disease and primary age-related tauopathy.", "offsetInBeginSection": 2612, "offsetInEndSection": 2762, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34687634", "text": "INTERPRETATION\n12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease.", "offsetInBeginSection": 2590, "offsetInEndSection": 2740, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31026619", "text": "It is currently unknown whether brain atrophy subtypes defined in Alzheimer's disease are clinically relevant during aging. We investigated participan", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21512418", "text": " Vitamin B supplements, such as folate, may help prevent homocysteine-related atrophy in Alzheimer's disease by possibly reducing homocysteine levels.", "offsetInBeginSection": 604, "offsetInEndSection": 754, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31219516", "text": "osterior cortical atrophy, the syndrome can provide important insights into selective vulnerability and phenotypic diversity. The present study descri", "offsetInBeginSection": 293, "offsetInEndSection": 443, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640f857d201352f04a00002b", "type": "factoid", "body": "What is CHARMS with respect to medical review of predictive modeling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35073384", "http://www.ncbi.nlm.nih.gov/pubmed/31762119", "http://www.ncbi.nlm.nih.gov/pubmed/33364802", "http://www.ncbi.nlm.nih.gov/pubmed/31441567", "http://www.ncbi.nlm.nih.gov/pubmed/31439598", "http://www.ncbi.nlm.nih.gov/pubmed/32583899", "http://www.ncbi.nlm.nih.gov/pubmed/33492724", "http://www.ncbi.nlm.nih.gov/pubmed/31090660", "http://www.ncbi.nlm.nih.gov/pubmed/32914178", "http://www.ncbi.nlm.nih.gov/pubmed/35493941"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31441567", "text": "For each model, we analysed (domains of CHARMS, Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies) the following: source of data, participants, outcome to be predicted, candidate predictors, sample size, missing data, model development, model performance, model evaluation, results and interpretation and discussion.", "offsetInBeginSection": 461, "offsetInEndSection": 611, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35073384", "text": "ssing medical researchers. The aim of this review was to assess the current level of knowledge with regard to regression modeling contained in such st", "offsetInBeginSection": 564, "offsetInEndSection": 714, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33364802", "text": "A checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) and the prediction model risk of bias assessment tool (PROBAST) were used for the data extraction process and critical appraisal.", "offsetInBeginSection": 517, "offsetInEndSection": 667, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31762119", "text": "However, these models should be developed appropriately (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modeling Studies [CHARMS] and Prediction model Risk Of Bias ASsessment Tool [PROBAST] statements).", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32914178", "text": "ng to treatments (predictive) in mental disorders.\n\n\nMETHODS\nPRISMA/RIGHT/CHARMS-compliant systematic review of the Web of Science, Cochrane Central R", "offsetInBeginSection": 314, "offsetInEndSection": 464, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35493941", "text": "We used the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS) checklist for the risk of bias assessment.", "offsetInBeginSection": 864, "offsetInEndSection": 1014, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32583899", "text": "The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodological appraisals of predictive models, based on the best available scientific evidence and through systematic reviews.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31090660", "text": "Studies were assessed using the checklist for critical appraisal and data extraction for systematic reviews of prediction modeling studies (CHARMS) checklist.", "offsetInBeginSection": 389, "offsetInEndSection": 539, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33492724", "text": "We followed the CHARMS recommendations (Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies), extracting the information from its 11 domains (Source of data, Participants, etc).", "offsetInBeginSection": 405, "offsetInEndSection": 555, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31439598", "text": "Data was extracted following the Checklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) checklist.", "offsetInBeginSection": 690, "offsetInEndSection": 840, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410eb95201352f04a00002e", "type": "list", "body": "Which splicing factors have been associated with alternative splicing in PLN R14del hearts?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35191471", "http://www.ncbi.nlm.nih.gov/pubmed/34383135", "http://www.ncbi.nlm.nih.gov/pubmed/36375644"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36375644", "text": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes.", "offsetInBeginSection": 1271, "offsetInEndSection": 1421, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34383135", "text": "ternative splicing subtype. Splicing factors that differentially expressed and alternatively spliced could result in global alternative splicing. Glob", "offsetInBeginSection": 803, "offsetInEndSection": 953, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35191471", "text": "Challenge of ex vivo hearts with isoproterenol and rapid pacing unmasked higher propensity for sustained ventricular tachycardia (VT) in hPLN-R14del relative to hPLN-WT.", "offsetInBeginSection": 914, "offsetInEndSection": 1064, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64162fb0690f196b5100001a", "type": "list", "body": "What are the most common mutation types in Duchenne muscular Dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29581631", "http://www.ncbi.nlm.nih.gov/pubmed/10422002", "http://www.ncbi.nlm.nih.gov/pubmed/23620649", "http://www.ncbi.nlm.nih.gov/pubmed/33039804", "http://www.ncbi.nlm.nih.gov/pubmed/33741226", "http://www.ncbi.nlm.nih.gov/pubmed/19555515"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19555515", "text": "d wasting. The most common are Duchenne muscular dystrophy and Becker muscular dystrophy, which result from mutations within the gene encoding dystrop", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23620649", "text": "The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations).", "offsetInBeginSection": 115, "offsetInEndSection": 265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29581631", "text": "BACKGROUND\nNonsense mutations in the dystrophin gene usually result in a severe Duchenne muscular dystrophy phenotype.\n\n\nFINDINGS\nWe describe a 7-year", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10422002", "text": "ivity were found in both diseases. Spontaneous activity--bizarre and fibrillation potentials, as well as sharp waves are more common for Duchenne type", "offsetInBeginSection": 773, "offsetInEndSection": 923, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226", "text": "ssociated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. These have been observed with higher freq", "offsetInBeginSection": 135, "offsetInEndSection": 285, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33039804", "text": "in children and is clinically characterized by progressive muscle degeneration and severe cardiomyopathy. In this study, renal epithelial cells were o", "offsetInBeginSection": 134, "offsetInEndSection": 284, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef3ebf36125a42600000a", "type": "factoid", "body": "What is the target of Litifilimab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26670814", "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "http://www.ncbi.nlm.nih.gov/pubmed/23099046", "http://www.ncbi.nlm.nih.gov/pubmed/21160809", "http://www.ncbi.nlm.nih.gov/pubmed/1477416", "http://www.ncbi.nlm.nih.gov/pubmed/35939578"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/1477416", "text": "ctivate already activated T cells remains unclear. Assuming that the T lymphocyte is the target site for CS, local therapy reaches only a small fracti", "offsetInBeginSection": 997, "offsetInEndSection": 1147, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "CONCLUSIONS\nIn a phase 2 trial involving participants with SLE, litifilimab was associated with a greater reduction from baseline in the number of swollen and tender joints than placebo over a period of 24 weeks.", "offsetInBeginSection": 2287, "offsetInEndSection": 2437, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "text": "CONCLUSIONS\nIn a phase 2 trial involving participants with cutaneous lupus erythematosus, treatment with litifilimab was superior to placebo with regard to a measure of skin disease activity over a period of 16 weeks.", "offsetInBeginSection": 2355, "offsetInEndSection": 2505, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "uired to determine the safety and efficacy of litifilimab for the treatment of SLE. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT02847598.).", "offsetInBeginSection": 2468, "offsetInEndSection": 2618, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "text": "ne the effect and safety of litifilimab for the treatment of cutaneous lupus erythematosus. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT028", "offsetInBeginSection": 2523, "offsetInEndSection": 2673, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26670814", "text": "Thus, recent data suggest that avoiding hyperpyrexia, rather than cooling \"per se,\" may be considered the main therapeutic target to avoid secondary brain damage after out-of-hospital cardiac arrest.", "offsetInBeginSection": 487, "offsetInEndSection": 637, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36069871", "text": "4, 8, 12, 16, and 20, with the primary end point of evaluating cutaneous lupus activity. The trial design was subsequently modified; adults with SLE, ", "offsetInBeginSection": 686, "offsetInEndSection": 836, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21160809", "text": "In this review we aim to explore the therapeutic potential and benefit of target therapy in the management of gastrointestinal soft tissue sarcoma and the possible complications or pitfalls of such an approach.", "offsetInBeginSection": 571, "offsetInEndSection": 721, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23099046", "text": "Based on this methodological motivation, the current experiments tested if the shape of a fixation target can be used to reduce eye movements during fixation.", "offsetInBeginSection": 651, "offsetInEndSection": 801, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939578", "text": "Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.", "offsetInBeginSection": 260, "offsetInEndSection": 410, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64136fbf201352f04a00003d", "type": "factoid", "body": "What is AUROC in context of predictive modeling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31093546", "http://www.ncbi.nlm.nih.gov/pubmed/31509205", "http://www.ncbi.nlm.nih.gov/pubmed/25885260", "http://www.ncbi.nlm.nih.gov/pubmed/31304302", "http://www.ncbi.nlm.nih.gov/pubmed/35509018", "http://www.ncbi.nlm.nih.gov/pubmed/32930711", "http://www.ncbi.nlm.nih.gov/pubmed/31807867", "http://www.ncbi.nlm.nih.gov/pubmed/35879562", "http://www.ncbi.nlm.nih.gov/pubmed/28323524"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31807867", "text": "RESULTS\nA training set (n\u2009=\u2009200) was used to develop predictive models of the EGFR mutation status (Model 1: area under the receiver operating characteristic curve [AUROC]\u2009=\u20090.910, 95% CI 0.861-0.945; Model 2: AUROC\u2009=\u20090.859, 95% CI 0.803-0.904; Model 3: AUROC\u2009=\u20090.711, 95% CI 0.643-0.773).", "offsetInBeginSection": 652, "offsetInEndSection": 802, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35879562", "text": "The predictive accuracy of an individual biomarker on cognitive impairment was evaluated using area under the receiver operating characteristic curve (AUROC), and multivariate logistic regression was applied to evaluate predictive accuracy of biomarkers on cognitive impairment; 178 subjects (41 PD, 31 VaD and 106 normal controls) were included.", "offsetInBeginSection": 360, "offsetInEndSection": 510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25885260", "text": "Accuracy in prediction of outcome (AC), sensitivity (SN), specificity (SP), and area under receiver-operating curve (AUROC) were compared between 3 models: KCC (INR, creatinine, coma grade, pH), CART analysis using only KCC variables (KCC-CART) and a CART model using new variables (NEW-CART).", "offsetInBeginSection": 652, "offsetInEndSection": 802, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31304302", "text": "Deep learning models achieved high accuracy for tasks such as predicting: in-hospital mortality (area under the receiver operator curve [AUROC] across sites 0.93-0.94), 30-day unplanned readmission (AUROC 0.75-0.76), prolonged length of stay (AUROC 0.85-0.86), and all of a patient's final discharge diagnoses (frequency-weighted AUROC 0.90).", "offsetInBeginSection": 1029, "offsetInEndSection": 1179, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35509018", "text": "Evaluation metrics methods specifically confusion matrix, accuracy, precision, recall, F1 score, and Area under the\u00a0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.", "offsetInBeginSection": 838, "offsetInEndSection": 988, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35509018", "text": "Evaluation metrics methods specifically confusion matrix, accuracy, precision, recall, F1 score, and Area under the\u00a0Receiver Operating Characteristics (AUROC) were used to evaluate the performance of predictive models.", "offsetInBeginSection": 846, "offsetInEndSection": 996, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31509205", "text": " (NPVs), positive predictive values (PPVs), and area under the receiver operating characteristic curve (AUROC), of machine learning models when predic", "offsetInBeginSection": 1023, "offsetInEndSection": 1173, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31093546", "text": "Rather, researchers use the area under the receiver operating characteristic (AUROC) as the key metric to gauge and report predictive performance ability.", "offsetInBeginSection": 112, "offsetInEndSection": 262, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32930711", "text": "RESULTS\nFor logistic regression, using UMLS delivered the optimal area under the receiver operating characteristics (AUROC) results in both dengue hemorrhagic fever (81.15%) and pancreatic cancer (80.53%) tasks.", "offsetInBeginSection": 1005, "offsetInEndSection": 1155, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28323524", "text": "Performance of prediction, accuracy of discrimination (area under the receiver operating characteristic curve [AUROC]), calibration, and validity of the two predictive models were investigated.", "offsetInBeginSection": 645, "offsetInEndSection": 795, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63fa13da201352f04a000001", "type": "yesno", "body": "Is PRP-40 regulation of microexons a conserved phenomenon?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30833759", "http://www.ncbi.nlm.nih.gov/pubmed/19278297", "http://www.ncbi.nlm.nih.gov/pubmed/25525873", "http://www.ncbi.nlm.nih.gov/pubmed/1765104", "http://www.ncbi.nlm.nih.gov/pubmed/32535349", "http://www.ncbi.nlm.nih.gov/pubmed/19451655", "http://www.ncbi.nlm.nih.gov/pubmed/34348142", "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "http://www.ncbi.nlm.nih.gov/pubmed/12043842"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142", "text": "d dysregulation of microexons but not conventionally sized exons. PRP-40 regulation of neuronal microexons is therefore a widely conserved phenomenon.", "offsetInBeginSection": 945, "offsetInEndSection": 1095, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19451655", "text": "poorly understood phenomenon by expressing fusion proteins of sheep prion protein and green fluorescent protein ((GFP)PrP) in N2a cells, with variable sequence context surrounding the start codon Met(1). (GFP)PrP expressed with the wild-type sequence was transported normally through the secretory pathway to the cell surface with acquisition of N-glycan groups, but two N-terminal fragments of (GFP)PrP were detected intracellularly, starting in frame from Met(17). When (GFP)PrP was expressed with a compromised Kozak sequence ((GFP)PrP*), dispersed intracellular fluorescence was observed. A similar switch from pericellular to intracellular PrP localization was seen when analogous constructs of sheep PrP, without inserted GFP, were expressed, showing that this phenomenon is not caused by the GFP tag", "offsetInBeginSection": 133, "offsetInEndSection": 939, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12043842", "text": "egenerative diseases in humans and animals. Although PrP is highly conserved evolutionarily, there is some sequence divergence among species; as a con", "offsetInBeginSection": 131, "offsetInEndSection": 281, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34348142", "text": "f neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependen", "offsetInBeginSection": 532, "offsetInEndSection": 682, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1765104", "text": "evealed that only two regions from positions -650 bp - -30 bp were highly conserved in all other PRP genes, PRP boxes 1 and 2. Box 1 at positions -112", "offsetInBeginSection": 510, "offsetInEndSection": 660, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32535349", "text": "The discovery and characterization of a network of highly conserved neuronal microexons has provided fundamental new insight into mechanisms underlying nervous system development and function, as well as an important basis for pathway convergence in autism spectrum disorder.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19278297", "text": "Altogether, our data uncover evolutionarily conserved roles of PrP in cell communication, which ultimately impinge on the stability of adherens cell junctions during embryonic development.", "offsetInBeginSection": 1265, "offsetInEndSection": 1415, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "text": "pectrum disorder. However, little is known of the patterns, regulatory mechanisms and roles of microexon splicing in cancer. We here examined the tran", "offsetInBeginSection": 114, "offsetInEndSection": 264, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25525873", "text": "ssociated with reduced levels of nSR100. The results thus reveal a highly conserved program of dynamic microexon regulation associated with the remode", "offsetInBeginSection": 858, "offsetInEndSection": 1008, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30833759", "text": "Neuronal microexons represent the most conserved class of alternative splicing in vertebrates, and are critical for proper brain development and function.", "offsetInBeginSection": 75, "offsetInEndSection": 225, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e15690f196b51000020", "type": "yesno", "body": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21171099", "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/35213020", "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "http://www.ncbi.nlm.nih.gov/pubmed/30171533", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "http://www.ncbi.nlm.nih.gov/pubmed/34553378"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35213020", "text": "Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different DMD exons.", "offsetInBeginSection": 37, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30171533", "text": "Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) and has developed from in vitro proof-of-concept studies to clinical trials targeting various single exons such as exon 45 (casimersen), exon 53 (NS-065/NCNP-01, golodirsen), and exon 51 (eteplirsen).", "offsetInBeginSection": 492, "offsetInEndSection": 642, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.", "offsetInBeginSection": 847, "offsetInEndSection": 997, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21171099", "text": "evel of serum creatine kinase. At the doses tested, C-EPO is not an effective therapeutic for the treatment of a mouse model of Duchenne muscular dyst", "offsetInBeginSection": 825, "offsetInEndSection": 975, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34553378", "text": "uscular dystrophy (DMD) is a degenerative muscle disease with no effective drug treatment. This study investigated the positive effects of fenofibrate", "offsetInBeginSection": 33, "offsetInEndSection": 183, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "se of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic patholo", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "ost common muscle disease found in male children. Currently, there is no effective therapy available for Duchenne muscular dystrophy patients. Therefo", "offsetInBeginSection": 36, "offsetInEndSection": 186, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "ith Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f02ceaf36125a426000015", "type": "summary", "body": "Which are the targets of Tirzepatide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36004653", "http://www.ncbi.nlm.nih.gov/pubmed/35921984", "http://www.ncbi.nlm.nih.gov/pubmed/35468325", "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "http://www.ncbi.nlm.nih.gov/pubmed/34186022", "http://www.ncbi.nlm.nih.gov/pubmed/34984793", "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "http://www.ncbi.nlm.nih.gov/pubmed/32730231", "http://www.ncbi.nlm.nih.gov/pubmed/35210595"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34186022", "text": "At 40 weeks, all tirzepatide doses were superior to placebo for changes from baseline in HbA1c, fasting serum glucose, bodyweight, and HbA1c targets of less than 7\u00b70% (<53 mmol/mol) and less than 5\u00b77% (<39 mmol/mol).", "offsetInBeginSection": 1695, "offsetInEndSection": 1845, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34984793", "text": "The development of high-dose GLP-1 RAs and the dual GLP-1/glucose-dependent insulinotropic peptide RA tirzepatide resulted in increasing numbers of people reaching HbA1c and body weight targets, with up to 62% attaining normoglycaemia with 15-mg tirzepatide.", "offsetInBeginSection": 1479, "offsetInEndSection": 1629, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32730231", "text": "Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.", "offsetInBeginSection": 66, "offsetInEndSection": 216, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468325", "text": "The aim of this substudy was to characterise the changes in liver fat content (LFC), volume of visceral adipose tissue (VAT), and abdominal subcutaneous adipose tissue (ASAT) in response to tirzepatide or insulin degludec in a subpopulation of the SURPASS-3 study.", "offsetInBeginSection": 233, "offsetInEndSection": 383, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35921984", "text": "RESULTS\nTreatment with tirzepatide stimulated catabolism of BCAAs/BCKAs in BAT, as demonstrated by increased labeling of BCKA-derived metabolites, and increases in levels of byproducts of BCAA breakdown, including glutamate, alanine, and 3-hydroxyisobutyric acid (3-HIB).", "offsetInBeginSection": 1111, "offsetInEndSection": 1261, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35830001", "text": "Tirzepatide (Mounjaro\u2122) is a single molecule that combines dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35210595", "text": "ptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires ev", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36050763", "text": "Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake.", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36004653", "text": "Tirzepatide is a unimolecular dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as once-weekly injection for the treatment of type 2 diabetes.", "offsetInBeginSection": 24, "offsetInEndSection": 174, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35468321", "text": "These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin.", "offsetInBeginSection": 3278, "offsetInEndSection": 3428, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640e2616201352f04a00002a", "type": "yesno", "body": "Is medical hydrology the same as Spa therapy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12406431", "http://www.ncbi.nlm.nih.gov/pubmed/33866427", "http://www.ncbi.nlm.nih.gov/pubmed/12831346", "http://www.ncbi.nlm.nih.gov/pubmed/10868019", "http://www.ncbi.nlm.nih.gov/pubmed/29455296", "http://www.ncbi.nlm.nih.gov/pubmed/12463465", "http://www.ncbi.nlm.nih.gov/pubmed/18829219", "http://www.ncbi.nlm.nih.gov/pubmed/12110784", "http://www.ncbi.nlm.nih.gov/pubmed/21563001"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29455296", "text": "PubMed/Medline, Embase, and Cochrane Library were searched for relevant articles in English or Italian about studies involving healthy and sub-healthy subjects or patients with a diagnosed disease about effects of balneotherapy, mud/peloid therapy, and spa therapy on serum and salivary cortisol levels.", "offsetInBeginSection": 67, "offsetInEndSection": 269, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33866427", "text": "Overall, retrieved scientific evidence suggests that spa therapy is beneficial for patients affected by some specific musculoskeletal conditions, with improvements potentially lasting up to 9 months.", "offsetInBeginSection": 619, "offsetInEndSection": 769, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21563001", "text": " In the Portuguese context this model is highly medicalized; in the Brazilian case, spa treatments are viewed as 'alternative' or 'complementary' therapy and are also related to religious philosophies", "offsetInBeginSection": 325, "offsetInEndSection": 525, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12406431", "text": " the treatment of RA in Europe and in the USA. The situation in SpA is different from RA because there is an unmet medical need, especially in AS, bec", "offsetInBeginSection": 640, "offsetInEndSection": 790, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29455296", "text": "Spa therapy with or without included mud/peloid therapy demonstrated the same potential to influence cortisol levels also in sub-healthy subjects and in patients with a diagnosed disease.", "offsetInBeginSection": 1399, "offsetInEndSection": 1585, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12831346", "text": "liximab and etanercept are approved in Europe. The situation in SpA is different to RA because there is an unmet medical need, especially in AS, since", "offsetInBeginSection": 675, "offsetInEndSection": 825, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10868019", "text": "therapy of SpA. The same is true for the knowledge on course, prognostic factors, and the socioeconomic consequences of these diseases. Furthermore, o", "offsetInBeginSection": 408, "offsetInEndSection": 558, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12110784", "text": "Within conservative approaches, spa hydrotherapy is popular among patients with venous disorders in Europe, but whether the practice is associated with health or social benefits remains controversial.", "offsetInBeginSection": 159, "offsetInEndSection": 309, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12463465", "text": "dence that treatment seems to be as effective as in adults. Risks are likely to be the same as in patients suffering from other forms of juvenile idio", "offsetInBeginSection": 1224, "offsetInEndSection": 1374, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18829219", "text": "y to administer physical therapy for CVD in France, but its efficacy has not been evaluated yet. This study aimed to assess the efficacy of balneother", "offsetInBeginSection": 169, "offsetInEndSection": 319, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410fa66201352f04a000034", "type": "summary", "body": "How does CYP1A2 relate to coffee consumption and apetite?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35905656", "http://www.ncbi.nlm.nih.gov/pubmed/19520064", "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "http://www.ncbi.nlm.nih.gov/pubmed/34564706", "http://www.ncbi.nlm.nih.gov/pubmed/18398030", "http://www.ncbi.nlm.nih.gov/pubmed/29976226", "http://www.ncbi.nlm.nih.gov/pubmed/28135712"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29976226", "text": "The urate-increasing GCKR, ABCG2, MLXIPL, and CYP1A2 alleles were associated with reduced daily coffee consumption, with the strongest associations for CYP1A2 (beta -0.30, P\u2009=\u00a08\u2009\u00d7\u200910-40), and MLXIPL (beta -0.17, P\u2009=\u00a03\u2009\u00d7\u200910-8), and weaker associations for GCKR (beta -0.07, P\u2009=\u00a03\u2009\u00d7\u200910-10) and ABCG2 (beta -0.09, P\u2009=\u00a02\u2009\u00d7\u200910-9).", "offsetInBeginSection": 1292, "offsetInEndSection": 1442, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706", "text": "Herein, we addressed the novel hypothesis that genetic variation in CYP1A2, a gene responsible for more than 95% of caffeine metabolism, differentially impacts the association of coffee consumption with appetite and BMI among individuals with different genetic predispositions to obesity.", "offsetInBeginSection": 278, "offsetInEndSection": 428, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28135712", "text": "tabolizes caffeine; thus, gene polymorphisms in ADORA2A and CYP1A2 may influence the effect coffee consumption has on PD risk.\n\n\nMETHODS\nIn a populati", "offsetInBeginSection": 291, "offsetInEndSection": 441, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34564706", "text": "CONCLUSIONS\nCYP1A2 rs762551 polymorphism modifies the association of habitual coffee consumption with BMI, in part by influencing appetite, energy intake and circulating levels of the orexigenic hormone asprosin.", "offsetInBeginSection": 1986, "offsetInEndSection": 2136, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "text": "erbs than in Swedes (P=0.0003).\n\n\nCONCLUSIONS\nHabitual heavy coffee consumption increases CYP1A2 activity. Polycyclic aromatic hydrocarbons formed dur", "offsetInBeginSection": 1326, "offsetInEndSection": 1476, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18157525", "text": "RESULTS\nDaily consumption of at least three cups of coffee significantly increased CYP1A2 enzyme activity in both Serbs (P=0.0002) and Swedes (P<0.0001).", "offsetInBeginSection": 602, "offsetInEndSection": 752, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28135712", "text": "LUSION\nWe corroborated results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our", "offsetInBeginSection": 1304, "offsetInEndSection": 1454, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18398030", "text": "CYP1A2 plays a key role in the metabolism of both estrogen and coffee. Women with higher coffee intake and the CYP1A2*1F A/A genotype have a ratio of ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35905656", "text": "onally, we hypothesize that CYP1A2 genotype can modulate serum glucose concentrations and lipid profile. A total of 421 participants aged 20 to 40 yea", "offsetInBeginSection": 753, "offsetInEndSection": 903, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19520064", "text": "eptor and DAT. The results demonstrate that caffeine alters the striatal CYP1A2, adenosine A(2A) receptor and DAT expressions in mice exposed to MPTP.", "offsetInBeginSection": 1388, "offsetInEndSection": 1538, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e73690f196b51000023", "type": "yesno", "body": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27807823", "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "http://www.ncbi.nlm.nih.gov/pubmed/30195785", "http://www.ncbi.nlm.nih.gov/pubmed/32691988", "http://www.ncbi.nlm.nih.gov/pubmed/30171536", "http://www.ncbi.nlm.nih.gov/pubmed/30526286", "http://www.ncbi.nlm.nih.gov/pubmed/31576784", "http://www.ncbi.nlm.nih.gov/pubmed/29752304", "http://www.ncbi.nlm.nih.gov/pubmed/35715998"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30526286", "text": "Eteplirsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most, controversial approvals ever made by the Food and Drug Administration of the United States.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30171536", "text": "ven to be powerful tools for treating neuromuscular diseases. The approval of Exondys 51 (eteplirsen) and Spinraza (nusinersen) for the treatment of p", "offsetInBeginSection": 60, "offsetInEndSection": 210, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823", "text": " developed by Sarepta Therapeutics. Intravenous eteplirsen has received accelerated approval from the US FDA for the treatment of Duchenne muscular dy", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35715998", "text": "sue in patients with Duchenne muscular dystrophy (DMD). Eteplirsen is a United States-approved treatment for patients with DMD and exon 51 skip-amenab", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32691988", "text": "In this year's neuromuscular Year in Review, we focus on Duchenne muscular dystrophy (DMD), reviewing studies that evaluate the respiratory effect of eteplirsen, the cardiopulmonary effects of ataluren, and a study comparing the use of spironolactone with eplerenone for the treatment of DMD-related cardiomyopathy.", "offsetInBeginSection": 232, "offsetInEndSection": 382, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "text": "BackgroundEteplirsen received accelerated FDA approval for treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping,", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31576784", "text": "ded promising results; the US Food and Drug Administration (FDA) approved eteplirsen (Exondys51) as the first exon-skipping drug for the treatment of ", "offsetInBeginSection": 713, "offsetInEndSection": 863, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30195785", "text": "herapeutics for Duchenne muscular dystrophy patients. However, the limited efficacy of eteplirsen underscores the importance to improve systemic deliv", "offsetInBeginSection": 90, "offsetInEndSection": 240, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34120909", "text": "Most frequent treatment-related adverse events were headache and vomiting; none led to treatment discontinuation.ConclusionsThis large, multicenter study contributes to the growing body of evidence for eteplirsen, confirming a positive treatment effect, favorable safety profile, and slowing of disease progression versus natural history.", "offsetInBeginSection": 1692, "offsetInEndSection": 1842, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29752304", "text": "METHODS\nClinical study 202 was an observational, open-label extension of the randomized, controlled study 201 assessing the safety and efficacy of eteplirsen in patients with DMD with a confirmed mutation in the DMD gene amenable to correction by skipping of exon 51.", "offsetInBeginSection": 226, "offsetInEndSection": 376, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03939f36125a42600001b", "type": "summary", "body": "What is the use of darolutamide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32003293", "http://www.ncbi.nlm.nih.gov/pubmed/28490267", "http://www.ncbi.nlm.nih.gov/pubmed/34866168", "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "http://www.ncbi.nlm.nih.gov/pubmed/33554636", "http://www.ncbi.nlm.nih.gov/pubmed/36087070", "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "http://www.ncbi.nlm.nih.gov/pubmed/33237495", "http://www.ncbi.nlm.nih.gov/pubmed/28801852"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28490267", "text": "nical efficacy and safety of darolutamide for the treatment of advanced prostate cancer are reviewed. The design of two ongoing phase III trials (ARAM", "offsetInBeginSection": 739, "offsetInEndSection": 889, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28801852", "text": " twice daily (Cohort 2) for 12\u00a0weeks. Primary endpoints: evaluate safety and pharmacokinetics of darolutamide.\n\n\nRESULTS\nOf 12 patients enrolled, 9 re", "offsetInBeginSection": 687, "offsetInEndSection": 837, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36087070", "text": "OBJECTIVE\nTo assess, the effect of darolutamide (a structurally distinct androgen receptor inhibitor) on urinary and bowel symptoms, using data from the phase III ARAMIS trial (NCT02200614) that showed darolutamide significantly reduced the risk of metastasis and death versus placebo.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33237495", "text": "Oral darolutamide (Nubeqa\u2122) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).", "offsetInBeginSection": 90, "offsetInEndSection": 240, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33554636", "text": "The trial showed that darolutamide in addition to hormone therapy increased the length of time that the trial participants were still alive for and lowered the risk of death by 31% compared with placebo (sugar pill) and hormone therapy.", "offsetInBeginSection": 723, "offsetInEndSection": 873, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34866168", "text": "BACKGROUND\nDarolutamide is a second-generation androgen receptor inhibitor approved for the treatment of nonmetastatic castration-resistant prostate cancer at a dosage of 600 mg orally twice daily.", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32003293", "text": "1. Darolutamide is a novel selective androgen receptor antagonist consisting of two pharmacologically equipotent diastereoisomers. The absorption, dis", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "text": "CONCLUSIONS\nIn this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points.", "offsetInBeginSection": 1836, "offsetInEndSection": 2106, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35179323", "text": "BACKGROUND\nDarolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32436836", "text": "D\nDarolutamide is recently approved for the treatment of non-metastatic castrate resistance prostate cancer. Hitherto, no stereoselective pharmacokine", "offsetInBeginSection": 9, "offsetInEndSection": 159, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64136664201352f04a00003b", "type": "list", "body": "What are the main clinical features of small-fiber neuropathy (SFN)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36331613", "http://www.ncbi.nlm.nih.gov/pubmed/30636091", "http://www.ncbi.nlm.nih.gov/pubmed/33802768", "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "http://www.ncbi.nlm.nih.gov/pubmed/24829596", "http://www.ncbi.nlm.nih.gov/pubmed/17868250", "http://www.ncbi.nlm.nih.gov/pubmed/23982054", "http://www.ncbi.nlm.nih.gov/pubmed/31639840", "http://www.ncbi.nlm.nih.gov/pubmed/30968230"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34075618", "text": "METHODS\nThis is a retrospective, observational study of sequential patients diagnosed with definite SFN (typical clinical features, normal nerve conduction studies, abnormal epidermal nerve fiber density) from the end of November 2016 to the middle of July 2019 at the Cantonal Hospital Lucerne, central Switzerland.", "offsetInBeginSection": 341, "offsetInEndSection": 491, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17868250", "text": "Small-fiber neuropathy (SFN) is diagnosed on the basis of clinical features and specialized tests of small-fiber function because standard nerve conduction studies are normal.", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31639840", "text": "esent, before the neuropathy evaluation. Etiology-specific treatment, lifestyle modification, and pain control are the key elements of SFN management.", "offsetInBeginSection": 512, "offsetInEndSection": 662, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35130356", "text": "rerequisites for treating SFN are an established diagnosis, knowledge about the symptoms and signs, and the etiology. Pain usually responds to oral/in", "offsetInBeginSection": 684, "offsetInEndSection": 834, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30636091", "text": "CONCLUSION\nOur results suggest that idio-SFN more specifically involved small sensory fibers than pSS-SFN, in which subtle dysfunction of larger sensory fibers and damage of distal autonomic sudomotor innervation may occur.", "offsetInBeginSection": 816, "offsetInEndSection": 966, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33802768", "text": "wn as SFN. This pathology may be the result of metabolic, toxic, immune-mediated, and/or genetic factors. Small fiber symptoms can be variable and inc", "offsetInBeginSection": 170, "offsetInEndSection": 320, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30968230", "text": "The main clinical features include neuropathic pain and autonomic disturbance, which are occasionally disclaimed due to outstanding fatigue, daily performance decline, anxiety, and depression.", "offsetInBeginSection": 288, "offsetInEndSection": 438, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24829596", "text": "al factors in patients with seemingly idiopathic SFN, such as impaired glucose tolerance. However, idiopathic SFN in young to middle-aged Swedish pati", "offsetInBeginSection": 1512, "offsetInEndSection": 1662, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23982054", "text": "We conducted the current study to analyze the clinical, immunologic, and neurophysiologic features of primary Sj\u00f6gren syndrome (pSS)-associated sensory small fiber neuropathies (SFNs).", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36331613", "text": "n's syndrome. We did not observe any differences in SFN-defining sensory plus symptoms. Furthermore, intraepidermal nerve fiber densities (IENFD) were", "offsetInBeginSection": 695, "offsetInEndSection": 845, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c53e690f196b51000012", "type": "factoid", "body": "When was Keytruda approved by the FDA for the treatment of metastatic non-small cell lung cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33058106", "http://www.ncbi.nlm.nih.gov/pubmed/27026676", "http://www.ncbi.nlm.nih.gov/pubmed/27821604", "http://www.ncbi.nlm.nih.gov/pubmed/24573551", "http://www.ncbi.nlm.nih.gov/pubmed/27920140", "http://www.ncbi.nlm.nih.gov/pubmed/29019253", "http://www.ncbi.nlm.nih.gov/pubmed/25797684", "http://www.ncbi.nlm.nih.gov/pubmed/27659911", "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "http://www.ncbi.nlm.nih.gov/pubmed/15962527"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24573551", "text": "On August 26, 2011, the U.S. Food and Drug Administration (FDA) approved crizotinib (XALKORI Capsules, Pfizer Inc.) for treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33058106", "text": "The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treat", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27821604", "text": "In 2015, the FDA approved an unprecedented number of new therapies for non-small cell lung cancer (NSCLC), among them therapies addressing specific genomic tumor subsets in the setting of development of resistance to first-line targeted therapy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27920140", "text": "andomized trials, the FDA approved the anti-PD-L1 agent atezolizumab in October. It is the first PD-L1 inhibitor approved for use in patients with met", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15962527", "text": "e cancer malignant pleural mesothelioma. Its accelerated approval for the second-line treatment of non-small-cell lung cancer followed in August 2004.", "offsetInBeginSection": 240, "offsetInEndSection": 390, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27659911", "text": "or patients with metastatic non-small cell lung cancer by the FDA in October, 2015. We present the first case, to the best of our knowledge, of a pati", "offsetInBeginSection": 547, "offsetInEndSection": 697, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29019253", "text": " remove its inhibitory effect and provoke an anti-tumor response. In October 2016, the Food and Drugs Administration (FDA) approved atezolizumab for t", "offsetInBeginSection": 260, "offsetInEndSection": 410, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27026676", "text": "UNLABELLED\n: On October 2, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab, a breakthrough therapy-de", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25797684", "text": "mphoma kinase rearranged metastatic non-small-cell lung cancer, on November 20, 2013. Crizotinib is a customized and improved therapeutic option for p", "offsetInBeginSection": 151, "offsetInEndSection": 301, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6417949d690f196b51000035", "type": "list", "body": "Which gene therapies are under investigation for Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2663627", "http://www.ncbi.nlm.nih.gov/pubmed/7804468", "http://www.ncbi.nlm.nih.gov/pubmed/12206800", "http://www.ncbi.nlm.nih.gov/pubmed/27594988", "http://www.ncbi.nlm.nih.gov/pubmed/17846262", "http://www.ncbi.nlm.nih.gov/pubmed/12206797", "http://www.ncbi.nlm.nih.gov/pubmed/12206795", "http://www.ncbi.nlm.nih.gov/pubmed/30119719", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/17217326"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30119719", "text": "Such translational research has led to the approval of two genetic therapies by the US Food and Drug Administration: eteplirsen for Duchenne muscular dystrophy and nusinersen for spinal muscular atrophy, which are both antisense oligonucleotides that modify pre-mRNA splicing.", "offsetInBeginSection": 420, "offsetInEndSection": 570, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17846262", "text": "gene therapy, an approach that demonstrates promise for treating Duchenne muscular dystrophy. Gene therapy is not limited to replacement of defective genes but also includes strategies using surrogate genes with alternative but effective means of improving cellular function or repairing gene mutations", "offsetInBeginSection": 146, "offsetInEndSection": 448, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2663627", "text": "mmon forms of muscular dystrophy, Duchenne muscular dystrophy and myotonic dystrophy. 5. Supportive therapies for muscular dystrophy patients now incl", "offsetInBeginSection": 741, "offsetInEndSection": 891, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12206797", "text": "Among the various approaches currently under investigation for dystrophin mutations that cause Duchenne muscular dystrophy is the use of chimeric RNA/DNA oligonucleotides (\"chimeraplasts\") to repair point mutations.", "offsetInBeginSection": 425, "offsetInEndSection": 575, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17217326", "text": "s Duchenne muscular dystrophy (DMD), which arises from defects in the dystrophin gene. Therapy specifically aimed at DMD is reviewed in the context of", "offsetInBeginSection": 333, "offsetInEndSection": 483, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7804468", "text": "A number of the viral vector systems, myoblast transfer, and direct injection techniques that are currently under investigation for the treatment of neuromuscular disorders are reviewed here.", "offsetInBeginSection": 240, "offsetInEndSection": 390, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "In the present review, we describe current methods of induced pluripotent stem cell generation and discuss their implications for the study, modeling, and development of cell-based therapies for Duchenne muscular dystrophy.", "offsetInBeginSection": 600, "offsetInEndSection": 750, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12206800", "text": "rophy gene which abort dystrophin synthesis. We have explored a gene correction therapy aimed at restoration of the reading frame in Duchenne muscular", "offsetInBeginSection": 107, "offsetInEndSection": 257, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12206795", "text": "We are now conducting a phase I safety clinical trial which will pave the way for future therapeutic gene therapy trials for Duchenne muscular dystrophy.", "offsetInBeginSection": 776, "offsetInEndSection": 926, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27594988", "text": "or DMD are currently available. In this review, we highlight the most advanced therapeutic strategies under investigation as potential DMD treatments.", "offsetInBeginSection": 478, "offsetInEndSection": 628, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f02a82f36125a426000013", "type": "yesno", "body": "Does CIDEB mutation protect from liver disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34646017", "http://www.ncbi.nlm.nih.gov/pubmed/24831470", "http://www.ncbi.nlm.nih.gov/pubmed/28719542", "http://www.ncbi.nlm.nih.gov/pubmed/35474605", "http://www.ncbi.nlm.nih.gov/pubmed/19661960", "http://www.ncbi.nlm.nih.gov/pubmed/32553626", "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "http://www.ncbi.nlm.nih.gov/pubmed/28585425", "http://www.ncbi.nlm.nih.gov/pubmed/20123130"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35939579", "text": " droplets.\n\n\nCONCLUSIONS\nRare germline mutations in CIDEB conferred substantial protection from liver disease. (Funded by Regeneron Pharmaceuticals.).", "offsetInBeginSection": 2112, "offsetInEndSection": 2262, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32553626", "text": "ole in growth of lipid droplets. Of these, CIDEB and CIDEC2/FSP27B are abundant in the liver, and the steatotic livers, respectively. Hepatocyte nucle", "offsetInBeginSection": 139, "offsetInEndSection": 289, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35474605", "text": "RESULTS\nThere was no evidence of association between rare germline variants or SNPs near five genes (ACVR2A, ALB, CIDEB, FOXO1 and TNRC6B) and risk or severity of liver disease.", "offsetInBeginSection": 889, "offsetInEndSection": 1039, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35474605", "text": "RESULTS\nThere was no evidence of association between rare germline variants or SNPs near five genes (ACVR2A, ALB, CIDEB, FOXO1 and TNRC6B) and risk or severity of liver disease.", "offsetInBeginSection": 919, "offsetInEndSection": 1087, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24831470", "text": "Cell death-inducing DFF45-like effector b (Cideb), an endoplasmic reticulum (ER)- and lipid droplet (LD)-associated protein, has been shown to play a critical role in maintaining hepatic lipid homeostasis by promoting the lipidation and maturation of VLDL particles.", "offsetInBeginSection": 89, "offsetInEndSection": 239, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28719542", "text": " its roles in the pathogenesis of UC are still ill-defined.\n\n\nMETHODS\nAcute colitis was induced with DSS in Cideb-null and wild-type mice, and the inflammation and oxidative stress were evaluated in the colonic mucosa. Moreover, triglyceride accumulation and oxidative stress were further analyzed in polarized Caco-2 cells with overexpression of Cideb.\n\n\nRESULTS\nOur present data indicated that Cideb-null mice were more susceptible to DSS-induced colitis", "offsetInBeginSection": 397, "offsetInEndSection": 853, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19661960", "text": "EC (r(2) = 0.32, P = 0.01) was strongly correlated with BMI, whereas CIDEB was not (r(2) = 0.01, P = 0.81). One year after surgery, CIDEC expression h", "offsetInBeginSection": 486, "offsetInEndSection": 636, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34646017", "text": "stinct hepatocyte clones per patient. CIDEB, which regulates lipid droplet metabolism in hepatocytes17-19, and GPAM, which produces storage triacylgly", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28585425", "text": "Our data showed that Cidea and Cidec were expressed at a high level in adipose tissue, and at a relatively high level in skeletal muscle, whereas Cideb was mainly expressed in the liver in both breeds of pig.", "offsetInBeginSection": 549, "offsetInEndSection": 699, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20123130", "text": "Cideb is a novel regulator in controlling cholesterol homeostasis in the liver. Therefore, Cideb could serve as an important therapeutical target for the treatment of atherosclerosis and cardiovascular diseases", "offsetInBeginSection": 1582, "offsetInEndSection": 1792, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64089b21201352f04a000021", "type": "summary", "body": "Can you summarize the function of CDK9?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21448926", "http://www.ncbi.nlm.nih.gov/pubmed/26083714", "http://www.ncbi.nlm.nih.gov/pubmed/30579871", "http://www.ncbi.nlm.nih.gov/pubmed/34811514", "http://www.ncbi.nlm.nih.gov/pubmed/18473913", "http://www.ncbi.nlm.nih.gov/pubmed/18753202", "http://www.ncbi.nlm.nih.gov/pubmed/31758083", "http://www.ncbi.nlm.nih.gov/pubmed/16720337", "http://www.ncbi.nlm.nih.gov/pubmed/12037670"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/18753202", "text": "We conclude that cdk9 plays a critical role in the optimization of expression of genes regulated by ICP22 and that one function of cdk9 in HSV-1-infected cells may be to bring ICP22 into the RNA Pol II transcriptional complex.", "offsetInBeginSection": 1485, "offsetInEndSection": 1635, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31758083", "text": "athological function of CDK9 in bacterial inflammatory diseases has never been explored. CDK9 inhibition or knock-down attenuated Porphyromonas gingiv", "offsetInBeginSection": 191, "offsetInEndSection": 341, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18473913", "text": "/or transcriptional control. CDK9 is the catalytic subunit of positive transcription elongation factor b (P-TEFb). CDK9 is the kinase of the TAK compl", "offsetInBeginSection": 135, "offsetInEndSection": 285, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12037670", "text": "pping within 101-161 aa of the bHLH region. Finally, cdk9 can phosphorylate MyoD in vitro, suggesting the possibility that cdk9/cycT2a regulation of m", "offsetInBeginSection": 1014, "offsetInEndSection": 1164, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16720337", "text": "This review primarily focuses on the mechanisms that modulate CDK9 activity and its recruitment to cellular genes, where it phosphorylates the C-terminal domain of RNA polymerase II (RNAPII) as well as negative elongation factors.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34811514", "text": "In this review, we summarize the current knowledge on the role of CDK9 in transcriptional regulation, epigenetic regulation, and different cellular factor interactions, focusing on new advances.", "offsetInBeginSection": 897, "offsetInEndSection": 1065, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34811514", "text": "In this review, we summarize the current knowledge on the role of CDK9 in transcriptional regulation, epigenetic regulation, and different cellular factor interactions, focusing on new advances.", "offsetInBeginSection": 943, "offsetInEndSection": 1093, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30579871", "text": "athogenesis of malignant tumors. However, the expression and function of CDK9 remain unknown in osteosarcomas. The purpose of this study is to assess ", "offsetInBeginSection": 101, "offsetInEndSection": 251, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21448926", "text": "t protein coding genes. Cdk9 kinase function is dependent upon phosphorylation of Thr186 in its T-loop. In this study, we examined kinases and signali", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26083714", "text": "CDK9 is the kinase subunit of positive transcription elongation factor b (P-TEFb) that enables RNA polymerase (Pol) II's transition from promoter-proximal pausing to productive elongation.", "offsetInBeginSection": 29, "offsetInEndSection": 187, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410eead201352f04a000030", "type": "summary", "body": "How does RBM24 control QT interval?", "documents": [], "snippets": []}, {"id": "64105502201352f04a00002d", "type": "yesno", "body": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21410696", "http://www.ncbi.nlm.nih.gov/pubmed/28648683", "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "http://www.ncbi.nlm.nih.gov/pubmed/35932452", "http://www.ncbi.nlm.nih.gov/pubmed/21954141", "http://www.ncbi.nlm.nih.gov/pubmed/22404693", "http://www.ncbi.nlm.nih.gov/pubmed/31479456", "http://www.ncbi.nlm.nih.gov/pubmed/35862363", "http://www.ncbi.nlm.nih.gov/pubmed/23726376", "http://www.ncbi.nlm.nih.gov/pubmed/30319901"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626905", "text": "The North Star Ambulatory Assessment (NSAA) is a validated 17-item functional rating scale and widely used to assess motor function in boys with Duchenne muscular dystrophy (DMD). The SARS-CoV-2 pandemic and subsequent Government 'lockdown' resulted in no face-to-face clinic visits hence the motor abilities were not monitored. The aim was to investigate whether the NSAA was feasible and reliable by video assessment", "offsetInBeginSection": 10, "offsetInEndSection": 428, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35932452", "text": "OBJECTIVE\nThe North Star Assessment for limb-girdle type muscular dystrophies (NSAD), a clinician-reported outcome measure (ClinRO) of motor performance, was initially developed and validated for use in dysferlinopathy, an autosomal recessive form of limb-girdle muscular dystrophy (LGMD R2/2B).", "offsetInBeginSection": 44, "offsetInEndSection": 194, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30319901", "text": "Currently, the 6-minute walk test (6-MWT) and the North Star Ambulatory Assessment (NSAA) are the primary outcome measures in clinical trials, but they are severely limited by the subjective consciousness and mood of patients, and can only be used in older and ambulatory boys.", "offsetInBeginSection": 279, "offsetInEndSection": 429, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35862363", "text": "The Motor Function Measure (general instrument), Duchenne Muscular Dystrophy Upper-limb Patient-reported Outcome Measure, North Star Ambulatory Assessment, and Myotonic Dystrophy Type 1 Activity and Participation Scale for Clinical Use (specific) are also recommended.", "offsetInBeginSection": 2182, "offsetInEndSection": 2332, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31479456", "text": "Functional variability among boys with Duchenne muscular dystrophy (DMD) is well recognised and complicates interpretation of clinical studies. We hypothesised that boys with DMD could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the North Star Ambulatory Assessment (NSAA) total score.", "offsetInBeginSection": 0, "offsetInEndSection": 344, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28648683", "text": "North Star Ambulatory Assessment in Brazilian Portuguese is a reliable and valid instrument to measure functional capacity in boys with Duchenne muscular dystrophy.", "offsetInBeginSection": 1382, "offsetInEndSection": 1532, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22404693", "text": "AIM\nWe evaluated ambulatory patients with Duchenne muscular dystrophy from the cardiovascular standpoint and studied the correlation between the results of electrocardiographic (ECG) findings, left ventricular ejection fraction (LVEF), troponin T and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and patients' North Star Ambulatory Assessment scores.", "offsetInBeginSection": 120, "offsetInEndSection": 364, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23726376", "text": "l Motor Scale (HFMSE) and North Star Ambulatory Assessment (NSAA) may also be useful in this young DMD population. Clinical evaluators from the MDA-DM", "offsetInBeginSection": 348, "offsetInEndSection": 498, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21410696", "text": "st evidence to support such tools. The North Star Ambulatory Assessment (NSAA) is a promising, clinician-rated scale with potential uses spanning clin", "offsetInBeginSection": 222, "offsetInEndSection": 372, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21954141", "text": "ur study indicates that the North Star Ambulatory Assessment is practical and reliable. It takes only 10 minutes to perform and incorporates both univ", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f032caf36125a42600001a", "type": "summary", "body": "What is the mechanism of action of rilzabrutinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34631841", "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "http://www.ncbi.nlm.nih.gov/pubmed/35417637"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33942286", "text": "tibodies. Rilzabrutinib is a new reversible, covalent BTK inhibitor demonstrating preclinical efficacy as monotherapy in canine pemphigus foliaceus.\n\n", "offsetInBeginSection": 202, "offsetInEndSection": 352, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33674445", "text": "ses. We examined the pharmacodynamic profile of rilzabrutinib and its preclinical mechanisms of action. In addition to potent and selective BTK enzyme", "offsetInBeginSection": 344, "offsetInEndSection": 494, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": ", or moxifloxacin (positive control). Primary objectives: part A - pharmacokinetics (PK) of rilzabrutinib \u00b1 ritonavir, safety, and optimal dose for Pa", "offsetInBeginSection": 660, "offsetInEndSection": 810, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34631841", "text": "\u03bcM). Conclusion: Remibrutinib and rilzabrutinib inhibit Btk-dependent pathways of platelet aggregation upon GPVI, VWF/GPIb, and Fc\u03b3RIIA activation. Re", "offsetInBeginSection": 1650, "offsetInEndSection": 1800, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35301810", "text": "This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects.", "offsetInBeginSection": 43, "offsetInEndSection": 193, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "\n\nCONCLUSIONS\nRilzabrutinib was active and associated with only low-level toxic effects at all dose levels. The dose of 400 mg twice daily was identif", "offsetInBeginSection": 1877, "offsetInEndSection": 2027, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34631841", "text": " platelet effects of two novel BTKi that exhibit a high (remibrutinib) or low (rilzabrutinib) selectivity for Btk over Tec. Methods and Results: Remib", "offsetInBeginSection": 524, "offsetInEndSection": 674, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "nisms of action: decreased macrophage (Fc\u03b3 receptor)-mediated platelet destruction and reduced production of pathogenic autoantibodies.\n\n\nMETHODS\nIn a", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417637", "text": "ously treated patients with immune thrombocytopenia. We used intrapatient dose escalation of oral rilzabrutinib over a period of 24 weeks; the lowest ", "offsetInBeginSection": 458, "offsetInEndSection": 608, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27324312", "text": "However, the cell type that senses O2 (the O2 sensor) and the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear.", "offsetInBeginSection": 256, "offsetInEndSection": 406, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641368ee201352f04a00003c", "type": "list", "body": "What are the  types/categories of adult diffuse gliomas.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34729052", "http://www.ncbi.nlm.nih.gov/pubmed/16700618", "http://www.ncbi.nlm.nih.gov/pubmed/35599404", "http://www.ncbi.nlm.nih.gov/pubmed/1666470", "http://www.ncbi.nlm.nih.gov/pubmed/28201752", "http://www.ncbi.nlm.nih.gov/pubmed/32640746", "http://www.ncbi.nlm.nih.gov/pubmed/35455749", "http://www.ncbi.nlm.nih.gov/pubmed/35578106", "http://www.ncbi.nlm.nih.gov/pubmed/34858308", "http://www.ncbi.nlm.nih.gov/pubmed/34817712"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16700618", "text": "epresentatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors. Especially in these diffuse gliomas, ", "offsetInBeginSection": 258, "offsetInEndSection": 408, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35599404", "text": "In the 5th edition of WHO classification of central nervous system tumors published in the end of 2021, one of the most important revisions is the division of the classification into adult-type and pediatric-type diffuse gliomas, and the latter is further divided into pediatric-type diffuse low-grade gliomas and pediatric-type diffuse high-grade gliomas.", "offsetInBeginSection": 510, "offsetInEndSection": 660, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34729052", "text": "The objectives of the current study were to assess the frequency of IDH mutation, ATRX expression loss, p53 overexpression, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopathological and histopathological features.", "offsetInBeginSection": 609, "offsetInEndSection": 759, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35578106", "text": "Many tumors have also been reconceptualized into new \"supercategories,\" including adult-type diffuse gliomas, pediatric-type diffuse low- and high-grade gliomas, and circumscribed astrocytic gliomas.", "offsetInBeginSection": 446, "offsetInEndSection": 596, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32640746", "text": "One of the most significant of these changes has been the division of adult astrocytomas into IDH-wildtype and IDH-mutant categories in addition to histologic grade as part of the main-line diagnosis, although a great deal of heterogeneity in the clinical outcome still remains to be explained within these categories.", "offsetInBeginSection": 494, "offsetInEndSection": 644, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35455749", "text": "This multi-omics analysis of the neurotransmission expression landscape of TCGA gliomas-which highlights the existence of neurotransmission-based glioma categories with different expression, epigenetic and inflammatory profiles-supports the existence of operational neurotransmitter signaling pathways in adult gliomas.", "offsetInBeginSection": 1307, "offsetInEndSection": 1457, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34817712", "text": "In the new 2021 WHO CNS tumor classification scheme, diffuse gliomas will be classified as either adult-type diffuse gliomas, pediatric-type diffuse high-grade gliomas, or pediatric-type diffuse low-grade gliomas.", "offsetInBeginSection": 815, "offsetInEndSection": 965, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1666470", "text": "ultifocal gliomas fall into four main categories: diffuse, multiple, multicentric and multiple-organ. Multicentric gliomas are uncommon lesions of the", "offsetInBeginSection": 1, "offsetInEndSection": 151, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28201752", "text": "thological analysis hesitated between a diffuse glioma, ganglioglioma, or pilocytic astrocytoma. Compared with IDH/H3 wild-type gliomas, H3 K27M-mutan", "offsetInBeginSection": 928, "offsetInEndSection": 1078, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34858308", "text": "ily of adult types of diffuse gliomas under the insignia of \"glioblastoma, IDH-wildtype.\" Of note, glioblastomas still can be detected in children whe", "offsetInBeginSection": 542, "offsetInEndSection": 692, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415ca99690f196b51000019", "type": "yesno", "body": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33630232", "http://www.ncbi.nlm.nih.gov/pubmed/34407361", "http://www.ncbi.nlm.nih.gov/pubmed/31783836", "http://www.ncbi.nlm.nih.gov/pubmed/29499327", "http://www.ncbi.nlm.nih.gov/pubmed/31501612", "http://www.ncbi.nlm.nih.gov/pubmed/31754328", "http://www.ncbi.nlm.nih.gov/pubmed/30784102", "http://www.ncbi.nlm.nih.gov/pubmed/32402724", "http://www.ncbi.nlm.nih.gov/pubmed/36077787", "http://www.ncbi.nlm.nih.gov/pubmed/33463538"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33463538", "text": "Chimeric antigen receptor (CAR) T cell therapy has shown considerable promise for hematologic malignancies, leading to the US Food and Drug Administration approval of two CAR T cell-based therapies for the treatment of B cell acute lymphoblastic leukemia and large B cell lymphoma.", "offsetInBeginSection": 85, "offsetInEndSection": 235, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31754328", "text": "Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US.", "offsetInBeginSection": 198, "offsetInEndSection": 348, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31501612", "text": "Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of cancer.", "offsetInBeginSection": 9, "offsetInEndSection": 159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34407361", "text": "Since the historic approval of tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia in 2017, chimeric antigen receptor (CAR) T-cell therapies have altered the treatment paradigm for hematologic malignancies.", "offsetInBeginSection": 81, "offsetInEndSection": 231, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31783836", "text": "The approval of chimeric antigen receptor (CAR) T cell therapies by the US Food and Drug Administration (FDA) and the European Commission have generated substantial momentum for these first-in-class therapies to be used in patients with B cell malignancies.", "offsetInBeginSection": 145, "offsetInEndSection": 295, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30784102", "text": "CD19-targeted chimeric antigen receptor (CAR)-modified T (CAR-T) cell immunotherapy has demonstrated impressive results in B-cell malignancies, and CAR-T cell therapies targeting other antigens are in development for other cancers.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36077787", "text": "Two anti-BCMA (B cell maturation antigen) CAR (Chimeric Antigen Receptor) T-cell therapies have been recently approved for relapsed and refractory multiple myeloma with excellent efficacy even in the heavily pre-treated patient population.", "offsetInBeginSection": 301, "offsetInEndSection": 451, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32402724", "text": "Chimeric antigen receptor (CAR) T cell therapy is currently approved for treatment of refractory B-cell malignancies. Response rates in these diseases", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33630232", "text": "of relapsed B-cell lymphoid neoplasms. There are currently three FDA-approved products: axicabtagene ciluecel and tisagenlecleucel for the treatment o", "offsetInBeginSection": 446, "offsetInEndSection": 596, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29499327", "text": "cell malignancies, Kymriah and Yescarta, have recently been approved by the Food and Drug Administration. The administration of CAR T cells is a compl", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e4b690f196b51000022", "type": "yesno", "body": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/35213020", "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/33407808", "http://www.ncbi.nlm.nih.gov/pubmed/36401026", "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "http://www.ncbi.nlm.nih.gov/pubmed/36401027"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35213020", "text": "Several exon skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of different DMD exons.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.", "offsetInBeginSection": 847, "offsetInEndSection": 997, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33407808", "text": "We demonstrate that the de novo dystrophin induced by exon skipping with PMO golodirsen is capable of conferring a histological benefit in treated patients with an increase in dystrophin associated proteins at the dystrophin positive regions of the sarcolemma in post-treatment biopsies.", "offsetInBeginSection": 709, "offsetInEndSection": 859, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "se of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic patholo", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34788571", "text": "The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of long-term golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401026", "text": "To date, four PMOs, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the FDA for the treatment of DMD.", "offsetInBeginSection": 316, "offsetInEndSection": 466, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "ommon muscle disease found in male children. Currently, there is no effective therapy available for Duchenne muscular dystrophy patients. Therefore, i", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027", "text": "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.", "offsetInBeginSection": 329, "offsetInEndSection": 479, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f043e4f36125a426000023", "type": "yesno", "body": "Is Baricitinib effective for Alopecia Areata?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36070222", "http://www.ncbi.nlm.nih.gov/pubmed/21572877", "http://www.ncbi.nlm.nih.gov/pubmed/28879192", "http://www.ncbi.nlm.nih.gov/pubmed/31323149", "http://www.ncbi.nlm.nih.gov/pubmed/12433000", "http://www.ncbi.nlm.nih.gov/pubmed/30745983", "http://www.ncbi.nlm.nih.gov/pubmed/31767273", "http://www.ncbi.nlm.nih.gov/pubmed/36239359", "http://www.ncbi.nlm.nih.gov/pubmed/32015973"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32015973", "text": "LEARNING POINTS\nBaricitinib is a small, orally active molecule that inhibits JAK-1 and JAK-2, which is used in the treatment of rheumatoid arthritis.Baricitinib has been also used in the treatment of psoriasis, alopecia areata and atopic dermatitis.Palmoplantar pustulosis is a rare cutaneous side effect of baricitinib.", "offsetInBeginSection": 721, "offsetInEndSection": 871, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36239359", "text": "% CI [2.38, 9.66], p .0001).\n\n\nCONCLUSION\nWhen compared to placebo, baricitinib is an effective and well-tolerated medication for the treatment of AA.", "offsetInBeginSection": 1237, "offsetInEndSection": 1387, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31767273", "text": "% and partial response; 46.7%).\n\n\nCONCLUSIONS\nTopical immunotherapy with SADBE is an effective treatment for alopecia areata. Therefore, the current t", "offsetInBeginSection": 1023, "offsetInEndSection": 1173, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31323149", "text": "These results indicate that, while 2DG is effective for some autoimmune diseases, it was not efficacious for the cell-mediated autoimmune mouse disease, alopecia areata.", "offsetInBeginSection": 718, "offsetInEndSection": 868, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36070222", "text": "Extensive subtypes of alopecia areata (AA) (totalis, universalis, or multifocal) still have no approved and effective treatments in Europe, although Janus kinase inhibitors, such as baricitinib, are promising treatments that have been recently approved by the FDA.", "offsetInBeginSection": 131, "offsetInEndSection": 281, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30745983", "text": "CONCLUSION\nOral mini-pulse methylprednisolone therapy is an effective and safe therapeutic option for alopecia areata without side effects, and the time of the treatment is short.", "offsetInBeginSection": 659, "offsetInEndSection": 809, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21572877", "text": "CONCLUSION\nA series of three monthly courses of medium-dose prednisolone pulse therapy is effective and well tolerated in most patients with active, multifocal alopecia areata.", "offsetInBeginSection": 1039, "offsetInEndSection": 1189, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12433000", "text": "Our cases indicate that combination therapy of topical SADBE with other therapies can be a choice for alopecia areata which is refractory to topical SADBE therapy alone.", "offsetInBeginSection": 0, "offsetInEndSection": 154, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12433000", "text": "Our cases indicate that combination therapy of topical SADBE with other therapies can be a choice for alopecia areata which is refractory to topical SADBE therapy alone.", "offsetInBeginSection": 1041, "offsetInEndSection": 1191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28879192", "text": "CONCLUSION\nSimvastatin/ezetimibe is not effective for treatment of alopecia areata, at least in severe and/or cases refractory to other treatments, either as monotherapy or as adjuvant.", "offsetInBeginSection": 1136, "offsetInEndSection": 1286, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64137616201352f04a000041", "type": "yesno", "body": "Anemia is not associated with chronic kidney failure", "documents": [], "snippets": []}, {"id": "6415bc8d690f196b5100000f", "type": "factoid", "body": "What is the estimated reduction in time when using online genetic counseling?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30121717", "http://www.ncbi.nlm.nih.gov/pubmed/26142383", "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "http://www.ncbi.nlm.nih.gov/pubmed/21240560"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": "We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively. We showed online genetic counseling to be effective, ", "offsetInBeginSection": 1548, "offsetInEndSection": 1698, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21240560", "text": "Genetic counselor time spent collecting family and medical history and providing face-to-face counseling for a new patient session decreased from an average of 85-69\u00a0min when using the computer-assisted data collection.", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26142383", "text": "d genetic counseling between the birth and the time of the study (mean 3.5 years). Of those not receiving genetic counseling, 71% said they were not o", "offsetInBeginSection": 407, "offsetInEndSection": 557, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30121717", "text": "y from a high school course (37.3%), college course (28.1%), or online (11.5%). Familiarity was associated with factors such as female gender (p\u2009=\u20090.0", "offsetInBeginSection": 658, "offsetInEndSection": 808, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64163660690f196b5100001d", "type": "yesno", "body": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/17541998", "http://www.ncbi.nlm.nih.gov/pubmed/35381069", "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "http://www.ncbi.nlm.nih.gov/pubmed/34693725", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "http://www.ncbi.nlm.nih.gov/pubmed/33104035"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.", "offsetInBeginSection": 886, "offsetInEndSection": 1104, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34693725", "text": "Conclusion: Deflazacort provides clinically meaningful delays in loss of physical milestones over 48\u00a0weeks compared with prednisone/prednisolone for patients with\u00a0nonsense mutation Duchenne muscular dystrophy.", "offsetInBeginSection": 911, "offsetInEndSection": 1061, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33104035", "text": " Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy", "offsetInBeginSection": 99, "offsetInEndSection": 271, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "text": "e muscular dystrophy (DMD). Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED). An ongoing double blind multicenter study", "offsetInBeginSection": 116, "offsetInEndSection": 266, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11038071", "text": "cort slows the progress of Duchenne muscular dystrophy (DMD) with fewer side effects than prednisone. In mdx mice, deflazacort treatment augments repa", "offsetInBeginSection": 7, "offsetInEndSection": 157, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "text": "ndpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differen", "offsetInBeginSection": 52, "offsetInEndSection": 202, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17541998", "text": "teroids used are prednisone/prednisolone and deflazacort. They are probably equally effective in stabilizing muscle strength but may have different si", "offsetInBeginSection": 411, "offsetInEndSection": 561, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35381069", "text": "leted the trial. Both daily prednisone and daily deflazacort were more effective than intermittent prednisone for the primary outcome (P\u2009<\u2009.001 for da", "offsetInBeginSection": 1497, "offsetInEndSection": 1647, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34693725", "text": "Aim: Compare efficacies of deflazacort and prednisone/prednisolone in providing clinically meaningful delays in loss of physical milestones in patients with nonsense mutation Duchenne muscular dystrophy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "text": " The two steroids were equally effective in improving motor function and functional performances. At 9 months, the average weight increase with respect to baseline value was 5% (2 kg) in the deflazacort group but 18% in the prednisone group (P < 0. 005), and the change remained significant after 12 months (P < 0.05). Other minor but nonsignificant side effects were observed. Steroid treatment with deflazacort appears to cause fewer side effects", "offsetInBeginSection": 812, "offsetInEndSection": 1260, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6402bc2d201352f04a000005", "type": "list", "body": "What are the targets of Mosunetuzumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19357322", "http://www.ncbi.nlm.nih.gov/pubmed/18824292", "http://www.ncbi.nlm.nih.gov/pubmed/17848073", "http://www.ncbi.nlm.nih.gov/pubmed/29697788", "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "http://www.ncbi.nlm.nih.gov/pubmed/1594433", "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "http://www.ncbi.nlm.nih.gov/pubmed/21440000", "http://www.ncbi.nlm.nih.gov/pubmed/35947358"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/19357322", "text": "The collective method combining at least three profiles identified 50, 25, 10, and 4% of the 30, 84, 41, and 864 phase III, II, I, and nonclinical trial targets as promising, including eight to nine targets of positive phase III results.", "offsetInBeginSection": 603, "offsetInEndSection": 753, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17848073", "text": "With the possible exception of extensive human vaccination, each of these approaches target post-spillover events and none of these avenues of research will have the slightest impact on reducing the risk of additional emergence of viruses or other pathogens from wildlife.", "offsetInBeginSection": 1056, "offsetInEndSection": 1206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35152430", "text": "The nuclear hormone receptors, farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) regulate many of these pathways: cholestasis, inflammation, and fibrosis, which is why they are being enthusiastically pursued as potential therapeutic targets in PBC.", "offsetInBeginSection": 1575, "offsetInEndSection": 1725, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12135991", "text": "ent Targets. The targets for health are based on improvements in infant, child and maternal mortality. Progress towards these goals will be used to as", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35947358", "text": "Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies.", "offsetInBeginSection": 76, "offsetInEndSection": 226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1594433", "text": "experiments, there were two redundant-targets conditions, one with identical targets and one with the different members of a class. In both of the GNG", "offsetInBeginSection": 492, "offsetInEndSection": 642, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35803286", "text": "INTERPRETATION\nFixed-duration mosunetuzumab has a favourable safety profile and induces high rates of complete remissions, allowing potential administration as an outpatient regimen, in patients with relapsed or refractory follicular lymphoma and two or more previous therapies.", "offsetInBeginSection": 3078, "offsetInEndSection": 3228, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18824292", "text": "The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiological conditions and their oncogenic potential in malignant disease.", "offsetInBeginSection": 1300, "offsetInEndSection": 1450, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21440000", "text": "e Th1 and Th2 inflammation precipitating symptoms. In both, innate and adaptive immunities are involved, providing a series of potential targets for t", "offsetInBeginSection": 450, "offsetInEndSection": 600, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29697788", "text": "Mucosal healing is currently recognized as the principal treatment target to be used in a \"treat to target\" paradigm, whereas histologic healing and normalization of biomarkers are being evaluated as potential future targets.", "offsetInBeginSection": 333, "offsetInEndSection": 483, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64144200201352f04a000043", "type": "yesno", "body": "Is anaphylaxis a results of mast cell activation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24586553", "http://www.ncbi.nlm.nih.gov/pubmed/28798744", "http://www.ncbi.nlm.nih.gov/pubmed/31156646", "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "http://www.ncbi.nlm.nih.gov/pubmed/23642289", "http://www.ncbi.nlm.nih.gov/pubmed/8092557", "http://www.ncbi.nlm.nih.gov/pubmed/35080312", "http://www.ncbi.nlm.nih.gov/pubmed/20526344", "http://www.ncbi.nlm.nih.gov/pubmed/25841551"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "text": "Moreover, AMPK\u03b12 knockdown or deficiency led to increased Fc\u03b5RI-mediated mast cell activation and anaphylaxis that were insensitive to U0126 or activator 5-aminoimidazole-4-carboxamide-1-\u03b2-4-ribofuranoside, suggesting that the suppression of Fc\u03b5RI signals by the inhibition of the ERK1/2 pathway relies largely on AMPK activation.", "offsetInBeginSection": 1404, "offsetInEndSection": 1554, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23642289", "text": "MCAS is a diagnosis of exclusion, and primary and secondary mast cell activation disorders as well as idiopathic anaphylaxis have to be ruled out before making the diagnosis.", "offsetInBeginSection": 1330, "offsetInEndSection": 1480, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20526344", "text": "arepsilonRI) on mast cells. However, the regulatory mechanism of mast cell activation is not completely understood. Here we identify an immunoglobulin", "offsetInBeginSection": 169, "offsetInEndSection": 319, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24948367", "text": "ed that mast cell activation and anaphylaxis are negatively regulated by AMP-activated protein kinase (AMPK). However, little is known about the relat", "offsetInBeginSection": 342, "offsetInEndSection": 492, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35080312", "text": "w clinical entities, such as the \u03b1-gal anaphylaxis. Anaphylaxis results from the massive activation of the mast cells (MCs). Thus, it is also necessar", "offsetInBeginSection": 465, "offsetInEndSection": 615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8092557", "text": "ermine whether mast cell activation, as demonstrated by elevated serum tryptase concentrations, can occur in protracted anaphylaxis.\n\n\nMETHODS\nCase re", "offsetInBeginSection": 448, "offsetInEndSection": 598, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28798744", "text": "Some usual clinical manifestations in anaphylaxis, such as angioedema or hypotension, or other less common, such as metrorrhagia, may be explained by the direct effect of the activation of the coagulation and contact system driven by mast cell mediators.", "offsetInBeginSection": 1449, "offsetInEndSection": 1599, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31156646", "text": "Results: SA considerably inhibited immunoglobulin (Ig) E-mediated mast cell activation, including \u03b2-hexosaminidase release, mRNA and protein expression of various cytokines, and PGD2 and LTC4 release.", "offsetInBeginSection": 898, "offsetInEndSection": 1048, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25841551", "text": "Anaphylaxis results from severe systemic mast cell activation. In addition to IgE-mediated and physical triggers, it may occur with a clonal mast cell", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24586553", "text": "r, Ang-1's function in mast cell activation and anaphylaxis diseases is unknown. The results of our study suggest that Ang-1 decreased lipopolysacchar", "offsetInBeginSection": 391, "offsetInEndSection": 541, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c6b6690f196b51000015", "type": "list", "body": "On which two clinical trials was the approval of Keytruda based?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28179454", "http://www.ncbi.nlm.nih.gov/pubmed/28235882", "http://www.ncbi.nlm.nih.gov/pubmed/30290675", "http://www.ncbi.nlm.nih.gov/pubmed/32272501", "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "http://www.ncbi.nlm.nih.gov/pubmed/28533473", "http://www.ncbi.nlm.nih.gov/pubmed/31580145"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/28179454", "text": "Key considerations for approval were determination of pembrolizumab dose and interpretation of tumor response-based endpoints using RECIST or immune-related RECIST.", "offsetInBeginSection": 1316, "offsetInEndSection": 1466, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": "rations prior to receiving pembrolizumab.Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically signif", "offsetInBeginSection": 835, "offsetInEndSection": 985, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28835513", "text": " receiving pembrolizumab.Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvemen", "offsetInBeginSection": 851, "offsetInEndSection": 1001, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31580145", "text": "METHODS\nTo establish a historic benchmark of risk and benefit, we searched Medline and Embase for clinical trials testing anti-cancer drugs in combination within 5\u2009years of approval by the Food and Drug Administration of 12 anti-cancer \"index\" drugs first licensed 2005-2007 inclusive.", "offsetInBeginSection": 225, "offsetInEndSection": 375, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31580145", "text": "The proportion of patients in our sample who participated in trials leading to an approval by the Food and Drug Administration or a National Comprehensive Cancer Network guideline recommendation was 12.7% with 5\u2009years of follow-up, and 22.3% among pairings for which there were 8\u2009years of follow-up.", "offsetInBeginSection": 1629, "offsetInEndSection": 1779, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32272501", "text": " Merkel cell carcinoma (MCC). Approval was based on Cancer Immunotherapy Trials Network protocol 9, also known as KEYNOTE-017 (NCT02267603), a multice", "offsetInBeginSection": 232, "offsetInEndSection": 382, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28533473", "text": "taining chemotherapy. Approval was based on the objective response rate (ORR) and duration of response (DoR) in a cohort of patients in a nonrandomize", "offsetInBeginSection": 317, "offsetInEndSection": 467, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28179454", "text": "or metastatic melanoma based on results of two randomized, open-label, active-controlled clinical trials. In trial PN006, 834 patients with ipilimumab", "offsetInBeginSection": 154, "offsetInEndSection": 304, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28235882", "text": "Approval was based on demonstration of objective tumor responses with prolonged response durations in 89 patients enrolled in a randomized, multicenter, open-label, dose-finding, and activity-estimating phase 1 trial.", "offsetInBeginSection": 443, "offsetInEndSection": 593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30290675", "text": " inclusion criteria. FDA approvals of these products were based on 22 pivotal trials. CMS NCDs were based on 27 original clinical trials; 14 clinical ", "offsetInBeginSection": 836, "offsetInEndSection": 986, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64178e34690f196b51000021", "type": "yesno", "body": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27506543", "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "http://www.ncbi.nlm.nih.gov/pubmed/33285037", "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "http://www.ncbi.nlm.nih.gov/pubmed/35634851", "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "http://www.ncbi.nlm.nih.gov/pubmed/36401027"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/12026233", "text": "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.", "offsetInBeginSection": 847, "offsetInEndSection": 997, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037", "text": "OBJECTIVE\nThe novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD).", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27506543", "text": "se of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic patholo", "offsetInBeginSection": 42, "offsetInEndSection": 192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28954035", "text": "ost common muscle disease found in male children. Currently, there is no effective therapy available for Duchenne muscular dystrophy patients. Therefo", "offsetInBeginSection": 36, "offsetInEndSection": 186, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27109613", "text": "es, most commonly as limb-girdle muscular dystrophy 2I. There is no effective therapy available. Glucocorticoid steroids have become the standard trea", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19179609", "text": "r dystrophy is a lethal neuromuscular disease that currently has no effective therapy. Transgenic overexpression of the alpha7 integrin in mdx/utrn(-/", "offsetInBeginSection": 16, "offsetInEndSection": 166, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027", "text": "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.", "offsetInBeginSection": 371, "offsetInEndSection": 521, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30796500", "text": "ith Duchenne muscular dystrophy experienced severe acute heart failure triggered by pneumonia. Levosimendan was effective in improving heart function.", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30544588", "text": "ive degeneration of skeletal and cardiac muscles. Currently, there is no effective therapy for this disorder. However, the technology of cell reprogra", "offsetInBeginSection": 186, "offsetInEndSection": 336, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35634851", "text": "OBJECTIVE\nTo evaluate long-term efficacy and safety of the anti-sense oligonucleotide viltolarsen in the treatment of patients with DMD amenable to exon 53 skipping therapy.", "offsetInBeginSection": 1649, "offsetInEndSection": 1799, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640410d1201352f04a000012", "type": "summary", "body": "What is Wilkie's syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35496747", "http://www.ncbi.nlm.nih.gov/pubmed/26969279", "http://www.ncbi.nlm.nih.gov/pubmed/19066831", "http://www.ncbi.nlm.nih.gov/pubmed/35304355", "http://www.ncbi.nlm.nih.gov/pubmed/30187852", "http://www.ncbi.nlm.nih.gov/pubmed/30254733", "http://www.ncbi.nlm.nih.gov/pubmed/35475250", "http://www.ncbi.nlm.nih.gov/pubmed/18419824", "http://www.ncbi.nlm.nih.gov/pubmed/34786223", "http://www.ncbi.nlm.nih.gov/pubmed/33083170"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35496747", "text": "Superior mesenteric artery (SMA) syndrome, also known as Cast syndrome, Wilkie's syndrome, or duodenal ileus, is a rare condition involving compression of the duodenum between the aorta and the SMA, primarily attributed to loss of the intervening mesenteric fat pad.", "offsetInBeginSection": 113, "offsetInEndSection": 265, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30187852", "text": "Wilkie's syndrome is a rare condition in which a decreased angle and distance between the superior mesenteric artery and aorta causes a compression of the third part of the duodenum, resulting ultimately in gastric dilation, gastric rupture and acute ischaemia of the bowel.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26969279", "text": "UNLABELLED\nSuperior mesenteric artery (SMA) syndrome, also named as Wilkie's syndrome, is a rare, potentially life-threatening gastro- vascular disorder and an uncommon cause of proximal bowel obstruction characterized by a compression of the third and final portion of the duodenum by the abdominal aorta and the overlying superior mesenteric artery.", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19066831", "text": "The superior mesenteric artery syndrome--also known as Wilkie's syndrome or as arteriomesenteric obstruction of the duodenum--is a rare condition of upper intestinal obstruction in which the third part of the duodenum is compressed by the overlying, narrow-angled superior mesenteric artery against the posterior structures.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34786223", "text": "Wilkie's syndrome is a very rare vascular alteration caused by congenital or acquired reduction of\u00a0space between the superior mesenteric artery (SMA) and\u00a0aorta.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35304355", "text": "Superior mesenteric artery syndrome (SMAS), also known as Wilkie's syndrome, is a rare cause of upper gastrointestinal tract obstruction. We report a ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30254733", "text": "Wilkie's syndrome is a rare cause of duodenal obstruction that can easily be missed at clinical practice. It is characterized by nausea, abdominal pai", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35475250", "text": "solved in all 37 patients (100%). Conclusion Wilkie's syndrome, although rare, is frequently late-diagnosed or underdiagnosed. In cases of failure of ", "offsetInBeginSection": 2721, "offsetInEndSection": 2871, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18419824", "text": "INTRODUCTION\nWilkie's syndrome, a rare cause of intestinal obstruction, is related to anatomical and mechanical factors associated with the reduction of retroperitoneal fat padding.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33083170", "text": "Superior mesenteric artery syndrome, or Wilkie's syndrome, is an unexpected cause of upper gastrointestinal tract obstruction. The exact incidence of ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641461bb201352f04a000046", "type": "summary", "body": "What is a PROTAC?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32338867", "http://www.ncbi.nlm.nih.gov/pubmed/10805251", "http://www.ncbi.nlm.nih.gov/pubmed/33642364", "http://www.ncbi.nlm.nih.gov/pubmed/28379698", "http://www.ncbi.nlm.nih.gov/pubmed/33406191", "http://www.ncbi.nlm.nih.gov/pubmed/36142231", "http://www.ncbi.nlm.nih.gov/pubmed/34240523", "http://www.ncbi.nlm.nih.gov/pubmed/35344835", "http://www.ncbi.nlm.nih.gov/pubmed/33160761", "http://www.ncbi.nlm.nih.gov/pubmed/32082969"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33160761", "text": "Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3 ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug discovery paradigm which has been widely used as biological tools and medicinal molecules with the potential of clinical application value.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28379698", "text": "Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide cereblon ligand.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33406191", "text": "A parallel, one-pot assembly approach to proteolysis targeting chimeras (PROTACs) is demonstrated utilizing activated esters generated in situ, and traceless Staudinger ligation chemistry.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35344835", "text": "The overexpression of PI3K kinase exists in many cancers. The proteolytic target chimera (PROTAC) technology is a new technology that uses the ubiquit", "offsetInBeginSection": 137, "offsetInEndSection": 287, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36142231", "text": "Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically, PROTAC consists of two terminals which are the ligand of the prote", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32082969", "text": "teins and aggregated proteins is a challenging goal. PROTAC proteolysis-targeting chimaera (PROTAC) technology may be the solution, considering its ab", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10805251", "text": "The commercial snake venom extract, Protac, is a specific activator of the anticoagulant zymogen, protein C (PC) in human plasma. This specific action", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32338867", "text": "Targeting protein degradation with Proteolysis-Targeting Chimeras (PROTACs) is an area of great current interest in drug discovery. Nevertheless, alth", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34240523", "text": "Development of proteolysis targeting chimeras (PROTACs) is emerging as a promising strategy for targeted protein degradation. However, the drug develo", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33642364", "text": "ases for which appropriate drugs and treatments are lacking. Proteolysis targeting chimera (PROTAC) technology is a novel strategy to solve this probl", "offsetInBeginSection": 135, "offsetInEndSection": 285, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410f839201352f04a000032", "type": "yesno", "body": "Can the concept of digital twins be applied in Precision Nutrition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33215237", "http://www.ncbi.nlm.nih.gov/pubmed/35701842", "http://www.ncbi.nlm.nih.gov/pubmed/35099399", "http://www.ncbi.nlm.nih.gov/pubmed/33377993", "http://www.ncbi.nlm.nih.gov/pubmed/32098079", "http://www.ncbi.nlm.nih.gov/pubmed/35617022", "http://www.ncbi.nlm.nih.gov/pubmed/36236216", "http://www.ncbi.nlm.nih.gov/pubmed/35607617"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35617022", "text": "\nDigital twins could provide an individualized early warning system that predicts the risk of future health conditions and recommends the most effective intervention to minimize that risk. These insights could significantly improve an individual's quality of life and healthy life expectancy and reduce population-level health burdens", "offsetInBeginSection": 2415, "offsetInEndSection": 2749, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35617022", "text": "An interdisciplinary approach is essential, as data science, artificial intelligence, and engineering concepts (digital twins) can identify key risk factors throughout the life course, potentially enabling personalized simulation of life-course risk for the development of multimorbidity.", "offsetInBeginSection": 424, "offsetInEndSection": 584, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33377993", "text": "The concept of digital twins has become increasingly popular in recent years. To exploit their full potential, integration of systems and data across ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36236216", "text": "e of cattle is about 5.197 after optimization. The digital twins model developed in this work can be used to forecast the cattle's future time budget.", "offsetInBeginSection": 800, "offsetInEndSection": 950, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35099399", "text": "The process-oriented ethical map we propose here can assist the developers of digital twins for personalized health care services in analyzing ethical risks in a more systematic manner.", "offsetInBeginSection": 2039, "offsetInEndSection": 2215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32098079", "text": "s under various damage/action conditions. The proposed method can serve as a foundation for further research on digital twins for large-scale structur", "offsetInBeginSection": 1282, "offsetInEndSection": 1432, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33215237", "text": "Furthermore, applications of Digital Twins for the academic education of future control and bioprocess engineers as well as for the training of future bioreactor operators will be described.", "offsetInBeginSection": 971, "offsetInEndSection": 1147, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35607617", "text": "The development of Digital Twins has enabled them to be widely applied to various fields represented by intelligent manufacturing. A Metaverse, which ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35701842", "text": "While the online data collection was successful, strategies need to be implemented to improve adherence, follow-up, control group credibility (for digital CBT-i), and twin recruitment rates (for twin trials).", "offsetInBeginSection": 2225, "offsetInEndSection": 2375, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef6edf36125a42600000d", "type": "summary", "body": "What is the mechanism of action of Teclistamab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32956453", "http://www.ncbi.nlm.nih.gov/pubmed/34388396", "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "http://www.ncbi.nlm.nih.gov/pubmed/8957109", "http://www.ncbi.nlm.nih.gov/pubmed/19719780", "http://www.ncbi.nlm.nih.gov/pubmed/36352205", "http://www.ncbi.nlm.nih.gov/pubmed/35749004"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36352205", "text": "Teclistamab (TECVAYLI\u00ae), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and Development for the treatment of relapsed or refractory multiple myeloma.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34388396", "text": "40 patients were administered the recommended phase 2 dose, identified as once per week subcutaneous administration of teclistamab at 1500 \u03bcg/kg, after 60 \u03bcg/kg and 300 \u03bcg/kg step-up doses (median follow-up 6\u00b71 months, IQR 3\u00b76-8\u00b72).", "offsetInBeginSection": 1620, "offsetInEndSection": 1770, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": "BACKGROUND\nTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.", "offsetInBeginSection": 28, "offsetInEndSection": 196, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "text": "Under more physiological conditions using healthy human whole blood, teclistamab mediated dose-dependent lysis of H929 cells and activation of T cells.", "offsetInBeginSection": 1020, "offsetInEndSection": 1170, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19719780", "text": "The mechanism of the long duration of action of salmeterol at beta(2)-adrenoceptors has long been a matter of debate, and is still unresolved. Szczuka", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "text": "BACKGROUND\nTeclistamab (JNJ-64007957), a B-cell maturation antigen \u00d7 CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.", "offsetInBeginSection": 50, "offsetInEndSection": 200, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004", "text": " recommended Phase II dose (RP2D). With active doses, exposure was maintained above the mean EC90. All patients who responded to the RP2D of teclistam", "offsetInBeginSection": 1295, "offsetInEndSection": 1445, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8957109", "text": "enesis of RA. The major effects of anti-TNFalpha therapy are in downregulating cytokine activity, and in reducing leucocyte trafficking to the joints.", "offsetInBeginSection": 529, "offsetInEndSection": 679, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32956453", "text": "fic antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells. Teclistamab induced cytotoxicity of BCMA+ ", "offsetInBeginSection": 306, "offsetInEndSection": 456, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166", "text": "CONCLUSIONS\nTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma.", "offsetInBeginSection": 1934, "offsetInEndSection": 2084, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640c8309201352f04a000024", "type": "list", "body": "The diagnosis of cholestasis is based on the elevations seen in what liver function tests?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30688121", "http://www.ncbi.nlm.nih.gov/pubmed/25180107", "http://www.ncbi.nlm.nih.gov/pubmed/24901263", "http://www.ncbi.nlm.nih.gov/pubmed/25923022", "http://www.ncbi.nlm.nih.gov/pubmed/24483054", "http://www.ncbi.nlm.nih.gov/pubmed/6246298", "http://www.ncbi.nlm.nih.gov/pubmed/7142434", "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "http://www.ncbi.nlm.nih.gov/pubmed/16825710"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30688121", "text": "Intrahepatic cholestasis of pregnancy is a diagnosis of exclusion and presents with unexplained pruritus, abnormal liver function tests, and increased serum bile acid levels, particularly in the third trimester of pregnancy.", "offsetInBeginSection": 35, "offsetInEndSection": 185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24901263", "text": "ence of a rash and deranged liver function tests, including raised serum bile acids. Intrahepatic cholestasis of pregnancy is associated with an incre", "offsetInBeginSection": 192, "offsetInEndSection": 342, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7142434", "text": "Serum liver function tests were estimated in 57 patients admitted to an Intensive Therapy Unit (ITU) with a diagnosis of septic shock. Following an initial biochemical disturbance, persisting hyperbilirubinaemia was associated with a poor prognosis. Post-mortem liver histology ", "offsetInBeginSection": 0, "offsetInEndSection": 278, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24483054", "text": "Report the case of patient 25 years old, with 32 weeks of gestation, which presents severe pruritus, jaundice, altered liver function tests and lipid profile, with presumptive diagnosis of intrahepatic cholestasis of pregnancy.", "offsetInBeginSection": 245, "offsetInEndSection": 395, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25180107", "text": "We present a case of a 57-year-old male who exhibited features of cholestatic jaundice including elevated liver function tests (LFTs) after taking cephalexin and showed improvement on removal of the offending agent.", "offsetInBeginSection": 256, "offsetInEndSection": 406, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6246298", "text": "histologic sections of tissue from 8 of 10 patients, and elevated bilirubin was seen in 7 of 10 patients with hepatic metastases and CEA levels greater than 1,000 ng/ml In contrast, histologically observed cholestasis and elevated bilirubin were seen in only 1 of 8 patients with CEA less than 500 ng/ml. A significant correlation was found between the plasma CEA level and histologically observed cholestasis (P less than 0.01). Serum bilirubin also correlated significantly (P less than 0.01), but alkaline phosphatase did not. Liver weight", "offsetInBeginSection": 604, "offsetInEndSection": 1146, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1858028", "text": " total hepatic DNA and RNA values, cholestatic livers demonstrated a significant threefold suppression of expected hepatocyte mitotic indexes 48 and 72 hours after PH, compared with livers after PH alone. Weight restoration in cholestatic livers was 11% +/- 5.2% compared with 40% +/- 4.3% in control livers (+/- SEM; p less than 0.001) 5 days after PH. Analysis of regenerating liver messenger RNA with complementary DNA probes", "offsetInBeginSection": 658, "offsetInEndSection": 1086, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16825710", "text": "The following investigations were performed: biochemical tests evaluating the function of the liver and cholestasis (serum bilirubin concentration and fractions, bile acids in serum, AlAT, AspAT, GGTP, FALK activities, serum electrophoresis, prothrombin index).", "offsetInBeginSection": 749, "offsetInEndSection": 899, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6246298", "text": "ntent, and 3) tumor spread and location. Liver function tests and plasma CEA recorded within 8 weeks of death, autopsy records of tumor spread, liver ", "offsetInBeginSection": 275, "offsetInEndSection": 425, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25923022", "text": "ice and lower abdominal pain. Liver tests revealed marked cholestasis and high alkaline phosphatase and bilirubin levels. Imaging showed a normal-appe", "offsetInBeginSection": 380, "offsetInEndSection": 530, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415c599690f196b51000013", "type": "factoid", "body": "Which company produces Keytruda?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35736598", "http://www.ncbi.nlm.nih.gov/pubmed/27398650", "http://www.ncbi.nlm.nih.gov/pubmed/26631501", "http://www.ncbi.nlm.nih.gov/pubmed/36223857", "http://www.ncbi.nlm.nih.gov/pubmed/30547369"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35736598", "text": "Pembrolizumab (Keytruda) is now approved as a single agent to treat advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient in those whose disease has progressed following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30547369", "text": "As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme) of pembrolizumab (Keytruda\u00ae) to submit evidence of its clinical and cost effectiveness for the treatment of locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.", "offsetInBeginSection": 79, "offsetInEndSection": 229, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27398650", "text": "ckade of PD1 is an important immunotherapeutic strategy for cancers. Pembrolizumab (Keytruda) is a humanized monoclonal anti-PD1 antibody that has bee", "offsetInBeginSection": 429, "offsetInEndSection": 579, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26631501", "text": "lopment of checkpoint inhibitors that target the PD-1/PD-L1 pathway. Pembrolizumab (MK-3475, lambrolizumab, Keytruda(\u00ae)) is a PD-1 inhibitor that has ", "offsetInBeginSection": 111, "offsetInEndSection": 261, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36223857", "text": ", six immune checkpoint inhibitors had been approved, with Keytruda and Opdivo accounting for the majority of global sales. Here, the impact of the di", "offsetInBeginSection": 84, "offsetInEndSection": 234, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64040edf201352f04a000011", "type": "yesno", "body": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34332638", "http://www.ncbi.nlm.nih.gov/pubmed/29170725", "http://www.ncbi.nlm.nih.gov/pubmed/34220427", "http://www.ncbi.nlm.nih.gov/pubmed/23050829", "http://www.ncbi.nlm.nih.gov/pubmed/35841241", "http://www.ncbi.nlm.nih.gov/pubmed/22503969", "http://www.ncbi.nlm.nih.gov/pubmed/15800139", "http://www.ncbi.nlm.nih.gov/pubmed/11570983", "http://www.ncbi.nlm.nih.gov/pubmed/34146512", "http://www.ncbi.nlm.nih.gov/pubmed/24648338"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29170725", "text": "SUMMARY\nDespite the considerable risk of cognitive impairment in people with diabetes and prediabetes, there is not enough evidence to support a specific treatment to prevent or slow mild cognitive impairment, or progression to Alzheimer's disease or related disorders.", "offsetInBeginSection": 736, "offsetInEndSection": 886, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24648338", "text": "A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer's disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.", "offsetInBeginSection": 57, "offsetInEndSection": 207, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35841241", "text": "CONCLUSIONS\nPrognostic tools for predicting cognitive decline and enriching clinical trials with participants at the highest risk of decline can improve trial quality, derisk endpoint failures, and accelerate therapeutic development in Alzheimer's disease.", "offsetInBeginSection": 2394, "offsetInEndSection": 2544, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34146512", "text": "e non-futility threshold.\n\n\nINTERPRETATION\nPioglitazone did not delay the onset of mild cognitive impairment. The biomarker algorithm demonstrated a 3", "offsetInBeginSection": 3689, "offsetInEndSection": 3839, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15800139", "text": "xifene.\n\n\nCONCLUSIONS\nRaloxifene at a dose of 120 mg/day, but not 60 mg/day, resulted in reduced risk of cognitive impairment in postmenopausal women.", "offsetInBeginSection": 1564, "offsetInEndSection": 1714, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34220427", "text": "The results of animal testing suggest that pioglitazone can be corrective as well as protective, and that its efficacy is enhanced in a time- and dose-dependent manner, but the dose-effect relations are not monotonic or sigmoid.", "offsetInBeginSection": 773, "offsetInEndSection": 923, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11570983", "text": "Large-scale clinical trials in high-risk populations are needed to determine whether lowering blood homocysteine levels reduces the risk of cognitive impairment and may delay the clinical onset of dementia and perhaps of Alzheimer's disease.", "offsetInBeginSection": 880, "offsetInEndSection": 1030, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22503969", "text": "ctively. Furthermore, pioglitazone significantly prevented the fall in GSH levels and elevation in brain MDA levels induced by scopolamine. These resu", "offsetInBeginSection": 1215, "offsetInEndSection": 1365, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34332638", "text": "ts with Alzheimer's disease. If this study demonstrates at least stabilisation of memory function and/or good tolerability, the next step will be to r", "offsetInBeginSection": 2310, "offsetInEndSection": 2460, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23050829", "text": " for maintaining cognitive function, but few studies are investigating these benefits in high-risk populations. The aim of AIBL Active is to determine", "offsetInBeginSection": 621, "offsetInEndSection": 771, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414638c201352f04a000047", "type": "factoid", "body": "Cereblon (CRBN)  has been identified as the target for what type of drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33777938", "http://www.ncbi.nlm.nih.gov/pubmed/22552008", "http://www.ncbi.nlm.nih.gov/pubmed/25016816", "http://www.ncbi.nlm.nih.gov/pubmed/28978850", "http://www.ncbi.nlm.nih.gov/pubmed/26186254", "http://www.ncbi.nlm.nih.gov/pubmed/34704527", "http://www.ncbi.nlm.nih.gov/pubmed/23565715", "http://www.ncbi.nlm.nih.gov/pubmed/26535672", "http://www.ncbi.nlm.nih.gov/pubmed/32865967", "http://www.ncbi.nlm.nih.gov/pubmed/32677118"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22552008", "text": "eblon (CRBN) has been identified as the primary teratogenic target of thalidomide. Our studies demonstrate that thalidomide, lenalidomide and another ", "offsetInBeginSection": 163, "offsetInEndSection": 313, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34704527", "text": "ogical processes. It has also been identified as the target for immunomodulatory drugs (IMiDs). CRBN ligands are also important components of proteoly", "offsetInBeginSection": 153, "offsetInEndSection": 303, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33777938", "text": "We had previously demonstrated that cereblon (CRBN) is the target of thalidomide embryopathy and acts as a substrate receptor for the E3 ubiquitin ligase complex, Cullin-Ring ligase 4 (CRL4CRBN) in zebrafish and chicks.", "offsetInBeginSection": 172, "offsetInEndSection": 322, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23565715", "text": "Cereblon (CRBN) has recently been identified as a target for immunomodulatory drugs (IMiDs) and its downregulation has been linked to resistance to lenalidomide.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26186254", "text": "Clinical interest in the measurement of Cereblon (CRBN), the primary target of the IMiDs immunomodulatory drugs lenalidomide and pomalidomide, has been fueled by its essential requirement for antitumor or immunomodulatory activity of both drugs in multiple myeloma (MM).", "offsetInBeginSection": 22, "offsetInEndSection": 172, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25016816", "text": "BN), has been identified as a direct molecular target for anti-neoplastic activities of IMiDs. CRBN has also been shown to be involved in IMiDs-mediat", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32865967", "text": "tly being explored as a therapeutic target for the treatment of acute myeloid leukemia. Molecular docking studies with CRBN and GSPT1 followed by anal", "offsetInBeginSection": 744, "offsetInEndSection": 894, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28978850", "text": "cluding multiple myeloma. Cereblon (CRBN) is a common primary target for IMiDs. It works as a substrate receptor of CRL4. Accumulating evidence has sh", "offsetInBeginSection": 242, "offsetInEndSection": 392, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32677118", "text": "cullin 4-RING ubiquitin ligase complex, and a binding target of immunomodulatory agents (IMiDs). CRBN is responsible for the pleiotropic effects of IM", "offsetInBeginSection": 59, "offsetInEndSection": 209, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26535672", "text": "We investigated the mechanisms of action of immuno-modulatory drug (lenalidomide) on the protein expression of cereblon (CRBN) and their therapeutic targets in the multiple myeloma cell line RPMI8226.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cdb033942b094c000012", "type": "yesno", "body": "Does silencing of SRRM4 promote microexon inclusion?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30100395", "http://www.ncbi.nlm.nih.gov/pubmed/33621242", "http://www.ncbi.nlm.nih.gov/pubmed/30995482", "http://www.ncbi.nlm.nih.gov/pubmed/35858306", "http://www.ncbi.nlm.nih.gov/pubmed/34445304", "http://www.ncbi.nlm.nih.gov/pubmed/25769695"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25769695", "text": "We further show that the Rest target gene and alternative splicing factor srrm4 is a key downstream regulator of maturation; Srrm4 knockdown partially restores the ability of FBMNs to migrate in rest mutants while preventing their precocious morphological maturation.", "offsetInBeginSection": 1396, "offsetInEndSection": 1546, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30995482", "text": "rtical neurons, overlapping SRRM3-SRRM4 activity regulates the development of interneuronal inhibition. In\u00a0vitro, SRRM3 and SRRM4 regulate the same sp", "offsetInBeginSection": 331, "offsetInEndSection": 481, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33621242", "text": " SRRM4 is further silenced in tumors, resulting in the suppression of normal microexon inclusion. Remarkably, SRRM4 is the most consistently silenced ", "offsetInBeginSection": 738, "offsetInEndSection": 888, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34445304", "text": "mpared to diabetes-resistant mice, correlating with a preferential skipping of SRRM4 target exons. The repression of Srrm4 expression is presumably me", "offsetInBeginSection": 1298, "offsetInEndSection": 1448, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30100395", "text": "While SRRM4 overexpression enhances SOX2 expression in both time- and dose-dependent manners in DU145 cells, RNA depletion of SOX2 compromises SRRM4-mediated stimulation of pluripotency genes.", "offsetInBeginSection": 1553, "offsetInEndSection": 1703, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35858306", "text": "Its deletion in zebrafish results in widespread down-regulation of microexon inclusion from early developmental stages, followed by other transcriptomic alterations, severe photoreceptor defects, and blindness.", "offsetInBeginSection": 788, "offsetInEndSection": 938, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03a20f36125a42600001c", "type": "list", "body": "Which drugs are included in the AZD7442?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/34548634", "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "http://www.ncbi.nlm.nih.gov/pubmed/35797235", "http://www.ncbi.nlm.nih.gov/pubmed/35871089", "http://www.ncbi.nlm.nih.gov/pubmed/35076282", "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "http://www.ncbi.nlm.nih.gov/pubmed/33532768"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34548634", "text": "We determined the structures of two human monoclonal antibodies-AZD8895 and AZD1061-which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor-binding domain (RBD) of SARS-CoV-2 to define the genetic and structural basis of neutralization.", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "text": "Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one containing tixagevimab and the other containing cilgavimab) of either 300 mg of AZD7442 or saline placebo, and they were followed for up to 183 days in the primary analysis.", "offsetInBeginSection": 764, "offsetInEndSection": 914, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33532768", "text": "To define the genetic and structural basis for SARS-CoV-2 neutralization, we determined the structures of two human monoclonal antibodies COV2-2196 and COV2-21301, which form the basis of the investigational antibody cocktail AZD7442, in complex with the receptor binding domain (RBD) of SARS-CoV-2.", "offsetInBeginSection": 236, "offsetInEndSection": 386, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "For this reason, a BLI assay was developed and qualified to evaluate the reliability of screening SARS-CoV-2 spike trimer variants against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neutralization susceptibility verification testing.", "offsetInBeginSection": 2176, "offsetInEndSection": 2326, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "For this reason, a BLI assay was developed and qualified to evaluate the reliability of screening SARS-CoV-2 spike trimer variants against anti-SARS-CoV-2 monoclonal antibodies (MAbs) tixagevimab and cilgavimab, the components of AZD7442, prior to in vitro pseudovirus neutralization susceptibility verification testing.", "offsetInBeginSection": 2184, "offsetInEndSection": 2334, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35076282", "text": "Here, we describe AZD7442, a combination of two mAbs, AZD8895 (tixagevimab) and AZD1061 (cilgavimab), that simultaneously bind to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2.", "offsetInBeginSection": 392, "offsetInEndSection": 542, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35443106", "text": "BACKGROUND\nThe monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models.", "offsetInBeginSection": 8, "offsetInEndSection": 158, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35993765", "text": "AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19).", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35871089", "text": "d change reduction\u2009~\u20092.7). Within the Evusheld /AZD7442 cocktail, Cilgavimab/AZD1061 is more active against BA.2 and BA.5 than against BA.1 (fold chan", "offsetInBeginSection": 681, "offsetInEndSection": 831, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35797235", "text": "AZD7442 (Evusheld) is a combination of two human anti-severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs), tixagevimab (AZD8895) and cilgavimab (AZD1061).", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640ddd9d201352f04a000028", "type": "list", "body": "What were the first 2 PD-1 inhibitors approved by the FDA in 2014?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28546286", "http://www.ncbi.nlm.nih.gov/pubmed/26285788", "http://www.ncbi.nlm.nih.gov/pubmed/30304963", "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "http://www.ncbi.nlm.nih.gov/pubmed/29357948", "http://www.ncbi.nlm.nih.gov/pubmed/30231333", "http://www.ncbi.nlm.nih.gov/pubmed/34196068"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/29357948", "text": "Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.", "offsetInBeginSection": 447, "offsetInEndSection": 597, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34196068", "text": "BACKGROUND\nTo review and summarize all U.S. Food and Drug Administration (FDA) approvals of programmed death (PD)-1 and PD-ligand 1 blocking antibodies (collectively referred to as PD-[L]1 inhibitors) over a 6-year period and corresponding companion/complementary diagnostic assays.", "offsetInBeginSection": 46, "offsetInEndSection": 196, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26285788", "text": "tration (FDA) was canagliflozin in March 2013. Two agents - dapagliflozin and empagliflozin - were FDA-approved in January and July 2014, respectively", "offsetInBeginSection": 599, "offsetInEndSection": 749, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30231333", "text": "For the treatment of advanced disease, approvals were obtained for the immune checkpoint inhibitors ipilimumab (2011), nivolumab (2014), pembrolizumab (2014), the combination ipilimumab plus nivolumab (2015), and the oncolytic virus vaccine laherparepvec (2015).", "offsetInBeginSection": 652, "offsetInEndSection": 802, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28546286", "text": "The FDA has approved one PD-1 checkpoint inhibitor, pembrolizumab, and two PD-L1 checkpoint inhibitors, avelumab and durvalumab, to treat metastatic urothelial carcinoma in patients whose disease continues to progress despite platinum-based chemotherapy.", "offsetInBeginSection": 40, "offsetInEndSection": 190, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30304963", "text": "FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab. Areas covered: Nivolumab is a fully human immunoglo", "offsetInBeginSection": 360, "offsetInEndSection": 510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "text": "and Drug Administration (FDA) has approved 2 PD-1 inhibitors, nivolumab and pembrolizumab, and several others are under investigation. Although PD-1 i", "offsetInBeginSection": 543, "offsetInEndSection": 693, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27058852", "text": "lignancies, FDA approval has been granted only in melanoma and in non-small cell lung cancer (NSCLC). Identifying biomarkers that can predict response", "offsetInBeginSection": 759, "offsetInEndSection": 909, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c4cf690f196b51000006", "type": "factoid", "body": "What is the difference between dermatillomania and skin picking disorder?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24091067", "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "http://www.ncbi.nlm.nih.gov/pubmed/23145387", "http://www.ncbi.nlm.nih.gov/pubmed/31605885", "http://www.ncbi.nlm.nih.gov/pubmed/33808008", "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "http://www.ncbi.nlm.nih.gov/pubmed/30920403", "http://www.ncbi.nlm.nih.gov/pubmed/30024442", "http://www.ncbi.nlm.nih.gov/pubmed/11891999"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23145387", "text": "thologic skin picking (skin picking disorder [SPD]) is a prevalent and disabling condition, which has received increasing study. It is timely to consi", "offsetInBeginSection": 13, "offsetInEndSection": 163, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "text": "Skin picking disorder, also termed dermatillomania is a condition that leads to repetitive\u00a0picking of their skin ending up in skin and soft tissue damage.", "offsetInBeginSection": 41, "offsetInEndSection": 191, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11891999", "text": "Although trichotillomania and pathological skin-picking are both characterized by repetitive self-injurious stereotypic behaviors, the former is classified as an impulse control disorder, while the latter is not given a specific diagnostic category in the Diagnostic and Statistical Manual of Mental Disorders (4th edition) [APA, 1994].", "offsetInBeginSection": 59, "offsetInEndSection": 209, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33808008", "text": "Dermatillomania or skin picking disorder (SPD) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life.", "offsetInBeginSection": 67, "offsetInEndSection": 217, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31605885", "text": "The present study is the first to investigate the quality of premonitory urges, as well as the temporal relationship between urges and skin picking behavior in individuals with skin picking disorder.", "offsetInBeginSection": 353, "offsetInEndSection": 503, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "text": "equently comorbid with depression and anxiety, which is underdiagnosed mainly by dermatologists. Assessment of skin picking disorder is based on instr", "offsetInBeginSection": 59, "offsetInEndSection": 209, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "text": "N\nThe comorbidity of factitious disorder and dermatillomania makes diagnosis very difficult. The limit between the two disorders is sometimes unclear.", "offsetInBeginSection": 1740, "offsetInEndSection": 1890, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30024442", "text": "the treatment of skin-picking disorder. However, these agents can cause opposite effects in some cases. There is a report on SSRI-induced skin-picking", "offsetInBeginSection": 257, "offsetInEndSection": 407, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31777356", "text": "Photographic measurement is a consistent way of assessing skin lesions, but it does not reflect the impact of skin picking disorder on the individual's life.", "offsetInBeginSection": 1690, "offsetInEndSection": 1840, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30920403", "text": "n an impulsive, repetitive manner despite the fact that no dermatological condition is detected. Skin picking disorder may also be comorbid in childre", "offsetInBeginSection": 104, "offsetInEndSection": 254, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eefa3bf36125a426000012", "type": "factoid", "body": "What causes Japanese Spotted Fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31645532", "http://www.ncbi.nlm.nih.gov/pubmed/30298801", "http://www.ncbi.nlm.nih.gov/pubmed/27197438", "http://www.ncbi.nlm.nih.gov/pubmed/23743544", "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "http://www.ncbi.nlm.nih.gov/pubmed/29968555", "http://www.ncbi.nlm.nih.gov/pubmed/29363442", "http://www.ncbi.nlm.nih.gov/pubmed/23209240", "http://www.ncbi.nlm.nih.gov/pubmed/15131221", "http://www.ncbi.nlm.nih.gov/pubmed/31186196"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35545515", "text": "Objectives\u3000We investigated the infectious causes and management of Japanese spotted fever (JSF) and severe fever thrombocytopenia syndrome (SFTS), whi", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23743544", "text": "anese spotted fever, who is the youngest reported patient so far. Tick-borne diseases, including Japanese spotted fever, should be included in the dif", "offsetInBeginSection": 58, "offsetInEndSection": 208, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15131221", "text": "To investigate the prevalence of spotted fever group rickettsioses in Korea, a serosurvey of Japanese spotted fever rickettsiosis in patients with acute febrile illness was conducted with an indirect immunofluorescence assay.", "offsetInBeginSection": 82, "offsetInEndSection": 232, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31186196", "text": "The study was conducted to determine the minimum inhibitory concentrations (MICs) of several antibacterial agents against Rickettsia japonica, which causes Japanese spotted fever.", "offsetInBeginSection": 56, "offsetInEndSection": 206, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30298801", "text": "Scrub typhus and Japanese spotted fever-both rickettsial diseases-are endemic and notifiable in Japan and may cause a fatal outcome without prompt treatment.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31645532", "text": "r (JSF) is an uncommon but potentially fatal infection transmitted by tick bites. We herein report a fulminant case of JSF infection that occurred in ", "offsetInBeginSection": 21, "offsetInEndSection": 171, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29363442", "text": "Spotted fever group rickettsioses are transmitted by several types of arthropods (including ticks, chiggers, fleas, and lice) and are distributed worldwide.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29968555", "text": "se spotted fever (JSF) is a zoonosis transmitted by ticks carrying the pathogen Rickettsia japonica. The classic triad of JSF symptoms is high fever, ", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27197438", "text": "rein on a case of severe Japanese spotted fever complicated by acute respiratory failure in Kobe City. A 70-year-old female presenting with general ma", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23209240", "text": " isolated in 1984 in Japan, is the type strain of R. japonica, the tick-borne agent of Japanese spotted fever. Here, we report the 1.33-Mb genome of t", "offsetInBeginSection": 30, "offsetInEndSection": 180, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640dde93201352f04a000029", "type": "summary", "body": "What is the difference between PD-1 and PD-L1?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36192730", "http://www.ncbi.nlm.nih.gov/pubmed/30851544", "http://www.ncbi.nlm.nih.gov/pubmed/34553519", "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "http://www.ncbi.nlm.nih.gov/pubmed/31190978", "http://www.ncbi.nlm.nih.gov/pubmed/33380881", "http://www.ncbi.nlm.nih.gov/pubmed/33816215", "http://www.ncbi.nlm.nih.gov/pubmed/26552662"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/36192730", "text": "The difference in mean change between the PD-1/PD-L1 inhibitors group and the chemotherapy group in QLQ-C30 and EQ-5D VAS was 3.64 (95% CI = 1.62, 5.66; P = 0.001) and 4.74 (95% CI = 2.65, 6.83; P = 0.001), which supported PD-1/PD-L1 inhibitors.", "offsetInBeginSection": 1244, "offsetInEndSection": 1394, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34553519", "text": "RESULTS\nThe ELISA results revealed higher circulating PD-1 and PD-L1 levels in dogs with tumors (2.9 [2.2-3.7] ng/mL; median [IQR] and 2.4 [1.4-4.4] ng/mL, respectively) than in healthy dogs (2.4 [1.9-3.0] ng/mL; p = 0.012 and 1.4 [0.9-2.1] ng/mL; p < 0.001, respectively).", "offsetInBeginSection": 508, "offsetInEndSection": 664, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33816215", "text": "In the present study, we systematically reviewed phase 2/3 trials of PD-1/PD-L1 inhibitors of advanced solid tumors that reported treatment effect (hazard ratio [HR]) in patients based on age (\u2265 75 years vs. < 75 years) and set anti-PD-1/PD-L1 monotherapy or combinational therapy as experimental arm.", "offsetInBeginSection": 488, "offsetInEndSection": 638, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "text": "The progression-free survival HRs favored PD-1/PD-L1 inhibitors over conventional treatment (0.88; 95% CI, 0.82 to 0.95, P = 0.002), whereas median month difference was just the opposite (-0.69 months, 95% CI, -1.14 to -0.24, P < 0.001).", "offsetInBeginSection": 1142, "offsetInEndSection": 1292, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33380881", "text": "ficity was lower. Further, we found that there is no statistically significant difference in efficacy between PD-1 and PD-L1 drugs.\n\n\nConclusions\nUrot", "offsetInBeginSection": 1380, "offsetInEndSection": 1530, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29545941", "text": "eutic options for several tumor types. Nonetheless, the differences in efficacy between PD-1/PD-L1 inhibitors and conventional treatments (chemotherap", "offsetInBeginSection": 136, "offsetInEndSection": 286, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26239088", "text": "The programmed cell death 1 (PD-1)/PD-L1 pathway inhibits host antitumor responses; however, little is known about how this pathway functions in the tumor microenvironment.", "offsetInBeginSection": 153, "offsetInEndSection": 303, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30851544", "text": "entage appeared to be more sensitive than the MFI methods. We found no correlation between PD-1 and PD-L1 expression levels and clinical features incl", "offsetInBeginSection": 1252, "offsetInEndSection": 1402, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31190978", "text": "Results: We demonstrated that PD-L1 expression was significantly increased in HGIN and EGC compared with LGIN, and both PD-1 and PD-L1 showed similar expression patterns, being mainly detected in infiltrating immune cells.", "offsetInBeginSection": 1067, "offsetInEndSection": 1217, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26552662", "text": "were 66.8% (44.8%-88.9%) and 54.0% (32.6-75.3%). The difference was not significant (Z = 0.77, p = 0.441). Anti-PD-1/PD-L1 antibody can serve as a pro", "offsetInBeginSection": 1311, "offsetInEndSection": 1461, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410f8b2201352f04a000033", "type": "summary", "body": "What would be the benefits of using a virtual digital twin in nutrition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32770212", "http://www.ncbi.nlm.nih.gov/pubmed/33174065", "http://www.ncbi.nlm.nih.gov/pubmed/29487613"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33174065", "text": "Incorporation of such variables in process operation can provide improved control performance with enhanced productivity.In this chapter the linear discrete Kalman filter, the extended Kalman filter and the unscented Kalman filters are described and a brief overview of applications of the Kalman filter and its non-linear extensions to bioreactors are presented.", "offsetInBeginSection": 657, "offsetInEndSection": 807, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29487613", "text": "This approach has the potential to deliver significant societal benefits, and can function as a social equalizer, by allowing for effective equalizing enhancement interventions.", "offsetInBeginSection": 1618, "offsetInEndSection": 1768, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32770212", "text": "tion in a personalized manner. Such a model may revolutionize the management of obesity and its comorbidities, and provide a pillar for healthy aging.", "offsetInBeginSection": 818, "offsetInEndSection": 968, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33174065", "text": "he process model and prediction algorithm to predict the bioprocess variables. These values could be used for optimization and control of the process.", "offsetInBeginSection": 1236, "offsetInEndSection": 1386, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64040af9201352f04a00000d", "type": "yesno", "body": "Is levosimendan effective for amyotrophic lateral sclerosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22206942", "http://www.ncbi.nlm.nih.gov/pubmed/32639325", "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "http://www.ncbi.nlm.nih.gov/pubmed/35278658", "http://www.ncbi.nlm.nih.gov/pubmed/21455838", "http://www.ncbi.nlm.nih.gov/pubmed/34536404", "http://www.ncbi.nlm.nih.gov/pubmed/34376973", "http://www.ncbi.nlm.nih.gov/pubmed/32714567", "http://www.ncbi.nlm.nih.gov/pubmed/23380453"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35278658", "text": "cations, such as injuries to the liver and kidney. To date, there is no effective treatment for amyotrophic lateral sclerosis. In this regard, investi", "offsetInBeginSection": 285, "offsetInEndSection": 435, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21455838", "text": "Better understanding of the aetiology of amyotrophic lateral sclerosis is necessary to develop effective treatment of this progressive neurodegenerative disease.", "offsetInBeginSection": 1081, "offsetInEndSection": 1231, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22206942", "text": "There is currently very limited effective pharmacological treatment for amyotrophic lateral sclerosis. Recent evidence suggests that caffeic acid phen", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32639325", "text": "range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral scler", "offsetInBeginSection": 1012, "offsetInEndSection": 1162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32714567", "text": "ange of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral scler", "offsetInBeginSection": 1009, "offsetInEndSection": 1159, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34536404", "text": "\nLevosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis. Although levosimendan was generally well tolerated", "offsetInBeginSection": 2740, "offsetInEndSection": 2926, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34376973", "text": "ac settings (eg, septic shock, pulmonary hypertension) and for non-cardiac applications (eg, amyotrophic lateral sclerosis). This narrative review out", "offsetInBeginSection": 619, "offsetInEndSection": 769, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34536404", "text": "ractile function of the human diaphragm. We aimed to evaluate the safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosi", "offsetInBeginSection": 230, "offsetInEndSection": 380, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31315908", "text": "OBJECTIVE\nTo evaluate the efficacy and safety of oral levosimendan in patients with amyotrophic lateral sclerosis (ALS). This phase II, randomised, do", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23380453", "text": "Clinically this complex presents with a levodopa-responsive parkinsonism and Amyotrophic Lateral Sclerosis and has been termed Brait-Fahn-Schwartz disease.", "offsetInBeginSection": 277, "offsetInEndSection": 427, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c0f7690f196b51000001", "type": "list", "body": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21070677", "http://www.ncbi.nlm.nih.gov/pubmed/17209350", "http://www.ncbi.nlm.nih.gov/pubmed/12788037", "http://www.ncbi.nlm.nih.gov/pubmed/25011434", "http://www.ncbi.nlm.nih.gov/pubmed/3826955", "http://www.ncbi.nlm.nih.gov/pubmed/8778603", "http://www.ncbi.nlm.nih.gov/pubmed/8040774", "http://www.ncbi.nlm.nih.gov/pubmed/24850570", "http://www.ncbi.nlm.nih.gov/pubmed/2208768", "http://www.ncbi.nlm.nih.gov/pubmed/25687292"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/8040774", "text": "Recurrent episodes of bizarre behavior were the only clinical symptoms that finally led to the diagnosis of ornithine transcarbamylase deficiency in an 8-year-old boy.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12788037", "text": "The symptoms and signs of ornithine transcarbamylase deficiency are discussed. When the condition occurs among males in the neonatal period it is like", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2208768", "text": "Somatic mosaicism for a deletion in the ornithine transcarbamylase gene is described in a boy with sporadic late onset ornithine transcarbamylase deficiency.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24850570", "text": "Our findings suggest a role for oxidative stress and aberrant glutamine metabolism in the acute clinical features of ornithine transcarbamylase deficiency even in the absence of hyperammonemia.", "offsetInBeginSection": 656, "offsetInEndSection": 806, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8778603", "text": "CONCLUSIONS\nGirls with symptomatic ornithine transcarbamylase deficiency who are treated with drugs that activate new pathways of waste-nitrogen excretion have fewer hyperammonemic episodes and a reduced risk of further cognitive decline.", "offsetInBeginSection": 1652, "offsetInEndSection": 1802, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3826955", "text": "ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia. The X-linked recessive inheritance results in neonatal death of af", "offsetInBeginSection": 14, "offsetInEndSection": 164, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17209350", "text": "d urea cycle disorder. Its clinical manifestations as lethargy, vomites, coma and cerebral edema are the effect of the higher concentration of the amm", "offsetInBeginSection": 65, "offsetInEndSection": 215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25687292", "text": "s are mostly due to hyperammonemia and include nausea, vomiting, lethargia and even convulsions and coma. Common neurological symptoms at presentation", "offsetInBeginSection": 264, "offsetInEndSection": 414, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25011434", "text": "manifestations of ornithine transcarbamylase deficiency included vomiting and seizure, which were the most frequent signs at admission. Two of the fou", "offsetInBeginSection": 859, "offsetInEndSection": 1009, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21070677", "text": "Ornithine transcarbamylase deficiency should be considered in the differential diagnosis of unexplained acute confusion, even without a suggestive family history.", "offsetInBeginSection": 2072, "offsetInEndSection": 2222, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63fa197c201352f04a000003", "type": "summary", "body": "How does SRSF11 contribute to metastasis potential of colorectal cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16148991", "http://www.ncbi.nlm.nih.gov/pubmed/36394206"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/16148991", "text": " contribute to metastasis and proliferation of tumor by stimulating the growth of tumor vessel. Both of VEGF and angiopoietin- 2 contribute to angioge", "offsetInBeginSection": 1334, "offsetInEndSection": 1484, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206", "text": "protein family, the involvement of SRSF11 in colorectal cancer (CRC) is unknown.\n\n\nMETHODS\nThe TCGA dataset and clinical samples were used to assess S", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206", "text": "NCLUSIONS\nSRSF11 exerts pro-metastatic effects in CRC by inhibiting the AS of HSPA12A pre-RNA. Our findings point to SRSF11-regulated HSPA12A splicing", "offsetInBeginSection": 1595, "offsetInEndSection": 1745, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36394206", "text": "pressed and associated with a poor prognosis. And SRSF11 played a pro-metastatic role in vitro and in vivo. By screening SRSF11-regulated AS events, w", "offsetInBeginSection": 1029, "offsetInEndSection": 1179, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eef60ef36125a42600000c", "type": "factoid", "body": "Olokizumab is tested for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27129012", "http://www.ncbi.nlm.nih.gov/pubmed/25648633", "http://www.ncbi.nlm.nih.gov/pubmed/24641941", "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "http://www.ncbi.nlm.nih.gov/pubmed/35455757", "http://www.ncbi.nlm.nih.gov/pubmed/33142700"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35455757", "text": "Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease and its treatment is an urgent problem of rheumatology. Olokizumab (OKZ) is a new", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27129012", "text": "Interleukin-6 (IL-6) is implicated in the pathophysiology of several inflammatory conditions. Olokizumab, a humanized anti-IL-6 monoclonal antibody, s", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33720587", "text": "AIM\nTo evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting.", "offsetInBeginSection": 442, "offsetInEndSection": 592, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24641941", "text": "OBJECTIVES\nThe aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity who had previously failed tumour necrosis factor (TNF) inhibitor therapy.", "offsetInBeginSection": 104, "offsetInEndSection": 254, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25648633", "text": "In this article, we review the mechanism of anti-IL-6 in the treatment of RA, provide the key efficacy and safety data from clinical trials of approved anti-IL-6, TCZ, as well as six candidate IL-6 blockers including sarilumab, ALX-0061, sirukumab, MEDI5117, clazakizumab, and olokizumab, and their future perspectives in the treatment of RA.", "offsetInBeginSection": 1076, "offsetInEndSection": 1226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "other domains) at week 12, with each olokizumab dose tested for superiority to placebo. We also tested the noninferiority of each olokizumab dose to a", "offsetInBeginSection": 772, "offsetInEndSection": 922, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34101570", "text": "OBJECTIVE\nThis study aimed to evaluate the long-term safety and efficacy of olokizumab (OKZ), an anti-interleukin (IL)-6 monoclonal antibody, in patients with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor-alpha inhibitors.", "offsetInBeginSection": 94, "offsetInEndSection": 244, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "those receiving it every 4 weeks.\n\n\nCONCLUSIONS\nIn patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was supe", "offsetInBeginSection": 2359, "offsetInEndSection": 2509, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33142700", "text": "Rheumatoid arthritis (RA) is the most common autoimmune disease worldwide. Epigenetic alternations of microRNAs (miRNAs) can contribute to its pathoge", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36001712", "text": "leukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.\n\n\nMETHODS\nIn a 24-week, phase 3, multicenter, placebo- and acti", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6413730e201352f04a00003f", "type": "summary", "body": "Please summarize the function of Trophinin-associated protein (TROAP)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30284652", "http://www.ncbi.nlm.nih.gov/pubmed/34077623", "http://www.ncbi.nlm.nih.gov/pubmed/35251990", "http://www.ncbi.nlm.nih.gov/pubmed/14633596", "http://www.ncbi.nlm.nih.gov/pubmed/30431120", "http://www.ncbi.nlm.nih.gov/pubmed/33500384", "http://www.ncbi.nlm.nih.gov/pubmed/29956806", "http://www.ncbi.nlm.nih.gov/pubmed/35708862", "http://www.ncbi.nlm.nih.gov/pubmed/30021381", "http://www.ncbi.nlm.nih.gov/pubmed/22201876"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/22201876", "text": "tics of trophinin protein and of the trophinin-associated proteins bystin and tastin. We then describe trophinin-mediated signal transduction in troph", "offsetInBeginSection": 294, "offsetInEndSection": 444, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35708862", "text": "BACKGROUND\nTrophinin-associated protein (TROAP) mediates embryonic transfer, regulates microtubules, and is associated with the biological behavior of various cancers.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29956806", "text": "Trophinin associated protein (TROAP) is a cytoplasmic protein required for spindle assembly and cell invasion; however, its biological function in cancer remains to be elucidated.", "offsetInBeginSection": 17, "offsetInEndSection": 167, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34077623", "text": "AIMS\nExperimental evidence demonstrated a crucial role of TROAP (Trophinin-associated protein) in regulating the cell proliferation of multiple tumors, while TROAP expression and function were largely unknown in glioma.", "offsetInBeginSection": 49, "offsetInEndSection": 199, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30284652", "text": "BACKGROUND\nTrophinin-associated protein (TROAP) is a cytoplasmic protein that functions as an adhesion molecule in processes such as embryo implantation, spindle formation, and cancer.", "offsetInBeginSection": 26, "offsetInEndSection": 176, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30021381", "text": "erified that trophinin associated protein (TROAP) was a direct target of miR-519d-3p in CRC cells. Using Oncomine database analysis, TROAP was confirm", "offsetInBeginSection": 1183, "offsetInEndSection": 1333, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33500384", "text": "Here, we demonstrated that ectopic expression of trophinin-associated protein (TROAP) dramatically drove HCC cell growth assessed by foci formation in monolayer culture, colony formation in soft agar and orthotopic liver transplantation in nude mice.", "offsetInBeginSection": 132, "offsetInEndSection": 282, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30431120", "text": "Trophinin associated protein (TROAP) is essential for centrosome integrity and proper bipolar organisation of spindle assembly during mitosis and plays an essential role in proliferation.", "offsetInBeginSection": 180, "offsetInEndSection": 330, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35251990", "text": " cancer cells for in vitro studies. Trophinin associated protein (TROAP) siRNA and treatment with or without actinomycin D was used in the cells for q", "offsetInBeginSection": 503, "offsetInEndSection": 653, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14633596", "text": "Both trophoblasts and endometrial epithelial cells express trophinin, which mediates apical cell adhesion through homophilic trophinin-trophinin binding.", "offsetInBeginSection": 154, "offsetInEndSection": 304, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410ed73201352f04a00002f", "type": "summary", "body": "How does SRSF11 promote metastasis of colon cancer?", "documents": [], "snippets": []}, {"id": "63f03fc8f36125a426000021", "type": "factoid", "body": "What disease can be treated with Lenacapavir?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/36272024", "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "http://www.ncbi.nlm.nih.gov/pubmed/36411257"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "BACKGROUND\nPatients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. Lenacapavir is a fi", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "CONCLUSIONS\nIn patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from baseline in viral load than those who received placebo.", "offsetInBeginSection": 2216, "offsetInEndSection": 2366, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "text": "SUMMARY\nOngoing studies are evaluating long-acting dosing of lenacapavir for treating HIV-1 in combination with other antiretrovirals and preventing HIV-1 as a single agent.", "offsetInBeginSection": 858, "offsetInEndSection": 1008, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35544387", "text": "In both cohorts, lenacapavir-related capsid substitutions that were associated with decreased susceptibility developed in 8 patients during the maintenance period (6 with M66I substitutions).", "offsetInBeginSection": 2006, "offsetInEndSection": 2156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "text": " conducted in a Phase 1b study of lenacapavir (Study 4072) in people with HIV (PWH).\n\n\nMETHODS\nMutations were inserted in a proviral DNA clone by site", "offsetInBeginSection": 308, "offsetInEndSection": 458, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187", "text": "ing antiretroviral classes and potent antiviral activity in persons with HIV-1. In persons with HIV-1, there was no preexisting resistance to lenacapa", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35028668", "text": "bo-controlled, dose-ranging, randomized study of lenacapavir in untreated PWH. Participants received a single dose of lenacapavir (up to 750 mg) or pl", "offsetInBeginSection": 794, "offsetInEndSection": 944, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411257", "text": "OBJECTIVES\nWe evaluated the HIV-1 capsid genetic variability and lenacapavir drug resistance-associated mutations (DRMs) among drug-naive individuals across HIV-1 clades.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024", "text": "regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of HIV-1 infection.", "offsetInBeginSection": 546, "offsetInEndSection": 696, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36411257", "text": " its predicted effectiveness for treatment and prevention, regardless of HIV-1 clades. The established conserved regions hence serve as a hallmark for", "offsetInBeginSection": 1256, "offsetInEndSection": 1406, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641365f6201352f04a00003a", "type": "yesno", "body": "Is Iron deficiency anemia a common complication of chronic kidney disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32077335", "http://www.ncbi.nlm.nih.gov/pubmed/26342303", "http://www.ncbi.nlm.nih.gov/pubmed/16198278", "http://www.ncbi.nlm.nih.gov/pubmed/35058395", "http://www.ncbi.nlm.nih.gov/pubmed/35644772", "http://www.ncbi.nlm.nih.gov/pubmed/17533016", "http://www.ncbi.nlm.nih.gov/pubmed/28682026", "http://www.ncbi.nlm.nih.gov/pubmed/30970355", "http://www.ncbi.nlm.nih.gov/pubmed/19325171"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35058395", "text": " development and treat complications including anemia. Anemia is one of the common complication of chronic kidney disease (CKD), which is a significan", "offsetInBeginSection": 223, "offsetInEndSection": 373, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35058395", "text": "The diagnosis of iron deficiency anemia in patients with CKD is complicated due to the relatively low predictive ability of routine serum iron markers (e.g., ferritin and transferrin saturation) and more invasive measurements such as bone marrow iron stores.", "offsetInBeginSection": 748, "offsetInEndSection": 898, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30970355", "text": "Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD patients suffer from both absolute and functional iron deficiency", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35644772", "text": "The link between these two factors has been described at length in the literature highlighting an association of malnutrition with iron deficiency considered itself as one of the causes of anemia in chronic kidney disease (non-dialysis and hemodialysis).", "offsetInBeginSection": 179, "offsetInEndSection": 401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32077335", "text": "Introduction: Anemia is a common extraintestinal complication of Crohn's disease (CD) mainly caused by iron deficiency, that affects the quality of life in CD patients.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28682026", "text": "Anemia is a frequent complication in chronic kidney disease (CKD), and it is often accompanied by various clinical symptoms. The primary cause of anem", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17533016", "text": "he nondialysis chronic kidney disease population. Limited data suggest that iron deficiency is common in patients with chronic kidney disease with ane", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26342303", "text": "Anemia is a common complication in patients with chronic kidney disease (CKD), mainly due to inadequate renal production of erythropoietin. In hemodia", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16198278", "text": "rnative because it requires less frequent injections. Iron deficiency is a major cause of anemia that is resistant to erythropoietin or darbepoetin al", "offsetInBeginSection": 520, "offsetInEndSection": 670, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19325171", "text": "o anemia. The other cause of anemia is deficiency of iron. Iron deficiency anemia is common in people with CKD and its importance in supporting erythr", "offsetInBeginSection": 316, "offsetInEndSection": 466, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6410ef9b201352f04a000031", "type": "yesno", "body": "Can modulation of KCNQ1 splicing prevent arrhythmias?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19687231", "http://www.ncbi.nlm.nih.gov/pubmed/23825229", "http://www.ncbi.nlm.nih.gov/pubmed/25087487", "http://www.ncbi.nlm.nih.gov/pubmed/32354382", "http://www.ncbi.nlm.nih.gov/pubmed/29843720", "http://www.ncbi.nlm.nih.gov/pubmed/32259418", "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "http://www.ncbi.nlm.nih.gov/pubmed/12566121", "http://www.ncbi.nlm.nih.gov/pubmed/19340287"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23608591", "text": "nd reduces arrhythmogenicity through the modulation of KCNQ1 splicing. We suggested that the modulation of KCNQ1 splicing may help prevent arrhythmia.", "offsetInBeginSection": 1615, "offsetInEndSection": 1765, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19340287", "text": " KCNE1 exerts its specific regulation of KCNQ1 activation via interactions between membrane-spanning segments of the two proteins. Less detailed attention has been focused on the role of the KCNE1 C-terminus in regulating channel behavior. We analyzed the effects of an LQT5 point mutation (D76N) and the truncation of the entire C-terminus (Delta70) on channel regulation, assembly and interaction. Both mutations significantly shifted voltage dependence of activation in the depolarizing direction and decreased I(Ks) current density. They also accelerated rates of channel deactivation but notably, did not affect activation kinetics", "offsetInBeginSection": 288, "offsetInEndSection": 924, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29843720", "text": "CONCLUSIONS\nIn MI mice, sEHI t-AUCB can repress miR-133, consequently stimulating KCNQ1 and KCNH2 mRNA and protein expression, suggesting a possible mechanism for its potential therapeutic application in ischemic arrhythmias.", "offsetInBeginSection": 2155, "offsetInEndSection": 2305, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32259418", "text": "redisposition to sudden cardiac death. This might be prevented by pharmacological modulation of KCNQ1/KCNE1. The prototypic KCNQ1/KCNE1 activator 4,4'", "offsetInBeginSection": 208, "offsetInEndSection": 358, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25087487", "text": "long QT rabbit model. KCNQ1 immunization prevented dofetilide-induced QTc prolongation and attenuated long QT-related arrhythmias.\n\n\nCONCLUSION\nInduct", "offsetInBeginSection": 1619, "offsetInEndSection": 1769, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32354382", "text": "els. Moreover, KCNQ1 antibodies were able to restore alterations in cardiac repolarization and most importantly to\u00a0suppress arrhythmias in LQTS2. KCNQ", "offsetInBeginSection": 1628, "offsetInEndSection": 1778, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12566121", "text": "The data suggest that electrical remodeling of the cardiac ventricle during hypertrophy involves regulation of the gene expression through modulation of transcriptional and translational regulatory pathways.", "offsetInBeginSection": 1405, "offsetInEndSection": 1589, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32354382", "text": "In models of LQTS type 2 (LQTS2) using human induced pluripotent stem cell-derived cardiomyocytes, KCNQ1 antibodies reverse the prolonged cardiac repolarization and abolish arrhythmic activities.", "offsetInBeginSection": 1316, "offsetInEndSection": 1510, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19687231", "text": "cally with this protein, implying that accessory subunit binding alone is not sufficient for channel modulation. These observations indicate that the ", "offsetInBeginSection": 1215, "offsetInEndSection": 1365, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23825229", "text": " These modifications are attenuated by the common Asian polymorphism KCNQ1 P448R, a genetic determinant preventing coxsackievirus-induced effects in vitro", "offsetInBeginSection": 971, "offsetInEndSection": 1125, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f57f7f33942b094c000006", "type": "summary", "body": "What is Catamenial pneumothorax?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/32190546", "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "http://www.ncbi.nlm.nih.gov/pubmed/28647447", "http://www.ncbi.nlm.nih.gov/pubmed/11715807", "http://www.ncbi.nlm.nih.gov/pubmed/31649227", "http://www.ncbi.nlm.nih.gov/pubmed/25981153", "http://www.ncbi.nlm.nih.gov/pubmed/19033519", "http://www.ncbi.nlm.nih.gov/pubmed/8693313", "http://www.ncbi.nlm.nih.gov/pubmed/17162716", "http://www.ncbi.nlm.nih.gov/pubmed/35530874"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/32190546", "text": "Catamenial pneumothorax (CP) is considered to be the most common form of thoracic endometriosis syndrome, which also includes catamenial hemothorax, catamenial hemopneumothorax, catamenial hemoptysis, and endometriosis lung nodules.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31649227", "text": "Catamenial pneumothorax is a rare condition. We report a case of a 36-year-old female who presented with dyspnoea every time before she had her regula", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17162716", "text": "Catamenial pneumothorax is an uncommon disease whose management is not consensual. We report the case of a patient who experienced several episodes of", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35530874", "text": "Catamenial pneumothorax is a unique condition associated with thoracic endometriosis. It often presents in females of reproductive age as a recurrent ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8693313", "text": "intrathoracic endometriosis is often assumed. Catamenial pneumothorax is rare and differs from primary spontaneous pneumothorax in its prevalence in t", "offsetInBeginSection": 150, "offsetInEndSection": 300, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11715807", "text": " catamenial pneumothorax. Catamenial pneumothorax is one of the forms of spontaneous pneumothorax. An integral part of the paper is a review of the li", "offsetInBeginSection": 78, "offsetInEndSection": 228, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19033519", "text": " the Greek meaning \"monthly\". Catamenial pneumothorax is a rare complication of endometriosis. A patient with a history of endometriosis presented to ", "offsetInBeginSection": 229, "offsetInEndSection": 379, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19670769", "text": "Catamenial pneumothorax is an rare disease which arise in women during menses, etiologically related to endometriosis of diaphragm and lung. The five ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25981153", "text": "CONCLUSION\nCatamenial pneumothorax is the most common presentation of thoracic endometriosis syndrome and should always be suspected in women in childbearing age.", "offsetInBeginSection": 1469, "offsetInEndSection": 1619, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28647447", "text": "BACKGROUND\nCatamenial pneumothorax is a rare but serious condition for women of reproductive age. We describe a trial of dienogest as hormonal therapy", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64144419201352f04a000045", "type": "summary", "body": "Please summarize haptenization.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1999650", "http://www.ncbi.nlm.nih.gov/pubmed/2953821", "http://www.ncbi.nlm.nih.gov/pubmed/7681423", "http://www.ncbi.nlm.nih.gov/pubmed/15237856", "http://www.ncbi.nlm.nih.gov/pubmed/23928507"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/15237856", "text": "he innate immune system, or haptenization eliciting an immunoallergic response of the adaptive immune system. Besides licensed drugs, herbal and natur", "offsetInBeginSection": 813, "offsetInEndSection": 963, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23928507", "text": "Her particular hepatic metabolism further increased the drugs' concentration, favoring the haptenization of liver proteins, eventually leading to the development of an autoimmune hepatitis.", "offsetInBeginSection": 526, "offsetInEndSection": 676, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/2953821", "text": "A rapid and simple method was developed for the haptenization of monoclonal antibodies (MAbs), to be used in immunoenzyme single and double staining techniques.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/1999650", "text": "dentical results. Using the NIP-FAb' conjugate identical target cell haptenization was readily achieved from experiment to experiment. Using conjugate", "offsetInBeginSection": 465, "offsetInEndSection": 615, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/7681423", "text": "y that MHC-associated, haptenated peptides create functional antigenic epitopes for TNP-specific CTL. Furthermore, using purified Kb-molecules and a p", "offsetInBeginSection": 511, "offsetInEndSection": 661, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c124690f196b51000002", "type": "yesno", "body": "Is trichotillomania encountered with equali frequency in males and females?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19479123", "http://www.ncbi.nlm.nih.gov/pubmed/16396185", "http://www.ncbi.nlm.nih.gov/pubmed/22056781", "http://www.ncbi.nlm.nih.gov/pubmed/2050379", "http://www.ncbi.nlm.nih.gov/pubmed/9193740", "http://www.ncbi.nlm.nih.gov/pubmed/30099694", "http://www.ncbi.nlm.nih.gov/pubmed/3681332", "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "http://www.ncbi.nlm.nih.gov/pubmed/29769783"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/2050379", "text": "nti-3.7, was identified. The G6PD deficiency gene frequency was 0.08 and 0.032 in males and females, respectively. Several cases with 2 abnormal genes", "offsetInBeginSection": 765, "offsetInEndSection": 915, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29769783", "text": "Trichotillomania is currently classified under obsessive and compulsive behavioral spectrum disorders and is often encountered in the younger population with research evidence of response to selective serotonin reuptake inhibitors (SSRIs), antipsychotics, and newer drugs such as N-acetyl cysteine.", "offsetInBeginSection": 573, "offsetInEndSection": 723, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/3681332", "text": "Intraventricular (IVC) conduction abnormalities were encountered with similar frequency in both sexes: in 12/33 (36%) of affected males and 10/32 (31%) of affected females.", "offsetInBeginSection": 545, "offsetInEndSection": 695, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30099694", "text": "ccur at any age but is observed more often in adolescents, with a strong predominance in females. Diagnosis of trichotillomania may be difficult, and ", "offsetInBeginSection": 146, "offsetInEndSection": 296, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19479123", "text": "lieving drugs and sedatives). Trichotillomania is a relatively common disorder; however, not all dermatologists are sufficiently prepared to treat it.", "offsetInBeginSection": 1042, "offsetInEndSection": 1192, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22056781", "text": " with fistulas (0.35%).  The frequency of the coronary artery anomalies was significantly higher in the females than the males (p = 0.001).  Of the co", "offsetInBeginSection": 888, "offsetInEndSection": 1038, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22056781", "text": "(1.34%), and 27 with fistulas (0.35%).  The frequency of the coronary artery anomalies was significantly higher in the females than the males (p = 0.0", "offsetInBeginSection": 873, "offsetInEndSection": 1023, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16396185", "text": "In females the frequency of polyandry was not different between treatments, and polyandrous females produced larger clutches, suggesting that polyandry might be adaptive.", "offsetInBeginSection": 757, "offsetInEndSection": 907, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9193740", "text": "ur algorithms by signal intensity-frequency histograms. Consistent with one a priori hypothesis, left putamen volume was found to be significantly sma", "offsetInBeginSection": 373, "offsetInEndSection": 523, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18970906", "text": "tatistical Manual of Mental Disorders, Fourth Edition, trichotillomania (85.3% females; mean age, 35.0 +/- 12.5). Comorbidity data were obtained with ", "offsetInBeginSection": 297, "offsetInEndSection": 447, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64041701201352f04a000017", "type": "list", "body": "What is the triad of the Eagle-Barrett Syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12579407", "http://www.ncbi.nlm.nih.gov/pubmed/24833922", "http://www.ncbi.nlm.nih.gov/pubmed/31864313", "http://www.ncbi.nlm.nih.gov/pubmed/30560020", "http://www.ncbi.nlm.nih.gov/pubmed/6231520", "http://www.ncbi.nlm.nih.gov/pubmed/35429431", "http://www.ncbi.nlm.nih.gov/pubmed/142096", "http://www.ncbi.nlm.nih.gov/pubmed/34209816"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/24833922", "text": "The Female Athlete Triad (Triad) represents a syndrome of three interrelated conditions that originate from chronically inadequate energy intake to compensate for energy expenditure; this environment results in insufficient stored energy to maintain physiological processes, a condition known as low energy availability.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35429431", "text": "Eagle-Barrett Syndrome (EBS) is a rare congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism.", "offsetInBeginSection": 65, "offsetInEndSection": 215, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6231520", "text": "Abdominal muscle deficiency, urinary tract abnormalities, and cryptorchidism are the three major features of the prune-belly syndrome, also referred to as triad syndrome or Eagle-Barrett syndrome.", "offsetInBeginSection": 48, "offsetInEndSection": 198, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/142096", "text": "dder in a 20 1/2 week fetus which subsequently was proven to have the prune belly or Eagle-Barrett syndrome. Serial sonograms were used to follow the ", "offsetInBeginSection": 76, "offsetInEndSection": 226, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34209816", "text": "mptoms. Watt W. Eagle identified two types: stylo-hyoid classic syndrome and stylo-carotid artery syndrome. The aim of this systematic review of the l", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31864313", "text": " variants of the Eagle syndrome. The classic one, mainly characterized by pain and dysphagia, and the carotid variant characterized by pain and someti", "offsetInBeginSection": 84, "offsetInEndSection": 234, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/12579407", "text": "BS) is characterized by the triad of abdominal muscle deficiency, urinary tract abnormalities, and cryptorchidism. Approximately 25% of patients with ", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34209816", "text": "d correlations between the onset of symptoms in Eagle syndrome and traumatic events and highlighted two possibilities: traumatic event could fracture ", "offsetInBeginSection": 693, "offsetInEndSection": 843, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30560020", "text": "owing triad of symptoms: deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism. The exact etiology is ", "offsetInBeginSection": 160, "offsetInEndSection": 310, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "640c85e9201352f04a000026", "type": "factoid", "body": "What cells proliferate in Mantle Cell Lymphoma", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22790016", "http://www.ncbi.nlm.nih.gov/pubmed/22058203", "http://www.ncbi.nlm.nih.gov/pubmed/20663948", "http://www.ncbi.nlm.nih.gov/pubmed/22371181", "http://www.ncbi.nlm.nih.gov/pubmed/10463985", "http://www.ncbi.nlm.nih.gov/pubmed/30065968", "http://www.ncbi.nlm.nih.gov/pubmed/34804720", "http://www.ncbi.nlm.nih.gov/pubmed/20688354", "http://www.ncbi.nlm.nih.gov/pubmed/11903572", "http://www.ncbi.nlm.nih.gov/pubmed/6362835"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/30065968", "text": "R-1 mantle cell lymphoma cell lines. Three therapeutic gene targets were examined for their effect on lymphoma growth. These included Cyclin D1, which is a cell cycle regulator, as well as Bcl-2 and Mcl-1, which prevent apoptosis. Gene knockdown with siRNA doses as low at 10 nM increased lymphoma cell apoptosis without carrier-mediated toxicity. Silencing of Cyclin D1 induced apoptosis despite a twofold \"compensation\" upregulation of Cyclin D2. Upon simultaneous silencing of all three genes, nearly 75% of JeKo-1 cells were apoptosing 3 days post-transfection. Furthermore, cells proliferated at only 15% of their pretreatment rate", "offsetInBeginSection": 642, "offsetInEndSection": 1278, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34804720", "text": "ive, rare form of non-Hodgkin lymphoma that arises from cells originating in the \"mantle zone.\" Here, we describe a case of mantle cell lymphoma assoc", "offsetInBeginSection": 44, "offsetInEndSection": 194, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22790016", "text": "Recently, the occurrence of cyclin D1-positive B cells with mantle cell lymphoma phenotype in the inner mantle zones of morphologically inconspicuous lymph nodes has been described and termed mantle cell lymphoma 'in situ'.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10463985", "text": "BACKGROUND\nMantle cell lymphoma is a mature, virgin B-cell neoplasm characterized immunologically by a panB+, CD5+, CD23-, cyclin D1+ phenotype and genetically by t(11;14)(q13;q32) with overexpression of the cyclin D1 (bcl-1) gene.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/6362835", "text": "Mantle-zone lymphoma (MZL) is a histologically distinctive variant of follicular lymphocytic lymphoma which is characterized by a proliferation of atypical small lymphoid cells as wide mantles around benign-appearing germinal centers.", "offsetInBeginSection": 86, "offsetInEndSection": 236, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20688354", "text": " B-cell lymphoma characterized by the t(11;14)(q13;q32). Mantle cell lymphomas exhibit a spectrum of morphologic findings, of which a subset of tumors is clinically aggressive with a high proliferation rate", "offsetInBeginSection": 42, "offsetInEndSection": 248, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20663948", "text": " cell survival signals by apoptosis and cell viability assays.\n\n\nRESULTS\nSTAT3 was constitutively phosphorylated in the Jeko-1 mantle cell lymphoma ce", "offsetInBeginSection": 583, "offsetInEndSection": 733, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11903572", "text": "The specimen from the relapse occurring 8 months later exhibited diffuse monomorphous cells co-expressing B-cell antigens and CD5, CD43 and cyclin D1, leading to the diagnosis of mantle cell lymphoma.", "offsetInBeginSection": 583, "offsetInEndSection": 733, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22371181", "text": "RESULTS\nCo-culture of mantle cell lymphoma cells and human stromal cells results in the survival and proliferation of primary mantle cell lymphoma cells for at least 7 months compared to mantle cell lymphoma cells cultured alone.", "offsetInBeginSection": 790, "offsetInEndSection": 940, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22058203", "text": "BACKGROUND\nCyclin D1-positive B cells are occasionally found in the mantle zones of reactive lymphoid follicles, a condition that has been called \"in situ mantle cell lymphoma\".", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415bb3c690f196b5100000e", "type": "factoid", "body": "What is the estimated cost reduction when using telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33027215", "http://www.ncbi.nlm.nih.gov/pubmed/28578759", "http://www.ncbi.nlm.nih.gov/pubmed/25833335", "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "http://www.ncbi.nlm.nih.gov/pubmed/34355459", "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "http://www.ncbi.nlm.nih.gov/pubmed/30559758"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25833335", "text": "Our randomized trial of telegenetics vs. in-person counseling found that telegenetics cost less than in-person counseling, with high satisfaction among those who attended.", "offsetInBeginSection": 1244, "offsetInEndSection": 1394, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/26785833", "text": "sfaction. One economic analysis published thus far reported lower costs than in-person care. We hypothesized that telegenetics can also be beneficial ", "offsetInBeginSection": 351, "offsetInEndSection": 501, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "text": "egenetics may increase patients' access to genetic counseling with affordable costs. However, before further developing DTC telegenetics, more researc", "offsetInBeginSection": 1059, "offsetInEndSection": 1209, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25833335", "text": "k post-CGC via telephone survey using validated scales. Total costs were $106 per telegenetics patient and $244 per in-person patient. Patient satisfa", "offsetInBeginSection": 751, "offsetInEndSection": 901, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34355459", "text": "In keeping with previous research, most genetics providers appraised telegenetics as a valuable addition to patient care (68%, N\u00a0=\u00a013) and hoped to offer it as an option beyond the pandemic (63%, N\u00a0=\u00a012).", "offsetInBeginSection": 2093, "offsetInEndSection": 2243, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33027215", "text": "GS\nImplementation of telegenetics in health systems is still limited, below 10%, somewhat higher for cancer genetic counseling. Nevertheless, telegene", "offsetInBeginSection": 190, "offsetInEndSection": 340, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "text": "legenetics. Telegenetics offered them convenience and reduced travel and associated costs. The majority of women described feeling a high degree of so", "offsetInBeginSection": 604, "offsetInEndSection": 754, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28578759", "text": "d were $16million and $14million respectively; an annual reduction of $85million in total. Conclusions The present study shows that the teledentistry ", "offsetInBeginSection": 1315, "offsetInEndSection": 1465, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f03ae6f36125a42600001d", "type": "factoid", "body": "What is the target of BI 1015550?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35569036", "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "http://www.ncbi.nlm.nih.gov/pubmed/36299369"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases.", "offsetInBeginSection": 2251, "offsetInEndSection": 2401, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of PDE4B. In vitro, BI 1015550 inhibits lipopolysaccharide (LPS)-induced tumor n", "offsetInBeginSection": 362, "offsetInEndSection": 512, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369", "text": "ics of BI 1015550 in healthy male subjects and patients with idiopathic pulmonary fibrosis (IPF).\n\n\nMethods\nIn the phase I study, 42 subjects were par", "offsetInBeginSection": 195, "offsetInEndSection": 345, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "that BI 1015550 was superior to placebo, 0.998). Among patients with background antifibrotic use, the median change in the FVC was 2.7 ml (95% credibl", "offsetInBeginSection": 1133, "offsetInEndSection": 1283, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783", "text": "To better understand the antifibrotic potential of BI 1015550 in vivo, its direct effect on human fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) was investigated in vitro.", "offsetInBeginSection": 1443, "offsetInEndSection": 1593, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "gent, prevented a decrease in lung function in patients with idiopathic pulmonary fibrosis. (Funded by Boehringer Ingelheim; 1305-0013 ClinicalTrials.", "offsetInBeginSection": 2035, "offsetInEndSection": 2185, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036", "text": "referential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis. Patients were randomly assigned in a 2:1 ratio to receive ", "offsetInBeginSection": 312, "offsetInEndSection": 462, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369", "text": "s. For both studies, the primary endpoint was the number of subjects with drug-related adverse events (AEs).\n\n\nResults\nIn the Phase I study, drug-rela", "offsetInBeginSection": 636, "offsetInEndSection": 786, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64089be7201352f04a000022", "type": "summary", "body": "Please summarize the difference between REMS and RMPs", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8529555", "http://www.ncbi.nlm.nih.gov/pubmed/10500302", "http://www.ncbi.nlm.nih.gov/pubmed/23244814", "http://www.ncbi.nlm.nih.gov/pubmed/31122578", "http://www.ncbi.nlm.nih.gov/pubmed/19665493"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/10500302", "text": "RMPs exhibit strong conservation of function across divergent species, and display species-specific interactions with SSB and enzymes to neutralize the SSB barrier to enzyme-ssDNA assembly.", "offsetInBeginSection": 356, "offsetInEndSection": 506, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19665493", "text": "The most typical differences between the two rebound groups were the increased cumulative time and longer average duration of REMS episodes without significant change in the number of these episodes of the small platform animals during the passive phase.", "offsetInBeginSection": 769, "offsetInEndSection": 919, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23244814", "text": " patient safety. Currently, neither agency provides specific guidance on how risk should be related to benefit either qualitatively or quantitatively.", "offsetInBeginSection": 1605, "offsetInEndSection": 1755, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31122578", "text": "l severity of illness; however, no studies have adequately addressed the intra or inter-rater reliability of the score.\n\n\nCONCLUSIONS\nThere is evidenc", "offsetInBeginSection": 1085, "offsetInEndSection": 1235, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8529555", "text": "In another condition subjects were given the same 4 h testing condition prior to sleep, the only difference being that they were instructed not to move their gaze; therefore only \"attentional movements\" were possible.", "offsetInBeginSection": 456, "offsetInEndSection": 606, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cd2f33942b094c000011", "type": "yesno", "body": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11473790", "http://www.ncbi.nlm.nih.gov/pubmed/28186082", "http://www.ncbi.nlm.nih.gov/pubmed/29484299", "http://www.ncbi.nlm.nih.gov/pubmed/28163190", "http://www.ncbi.nlm.nih.gov/pubmed/34155820", "http://www.ncbi.nlm.nih.gov/pubmed/17565696", "http://www.ncbi.nlm.nih.gov/pubmed/29671263", "http://www.ncbi.nlm.nih.gov/pubmed/23303910", "http://www.ncbi.nlm.nih.gov/pubmed/30934641", "http://www.ncbi.nlm.nih.gov/pubmed/35274098"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23303910", "text": "The flipside of these highly integrated functions is that they make small GTPase regulators susceptible to biochemical abnormalities that are directly correlated with diseases, notably a striking number of missense mutations in congenital diseases, and susceptible to bacterial mimics of GEFs, GAPs, and GDIs that take command of small GTPases in infections.", "offsetInBeginSection": 1098, "offsetInEndSection": 1248, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35274098", "text": "In patients with myotonic dystrophy type 1 (DM1), dysregulation of RNA-binding proteins like MBNL and CELF1 leads to alternative splicing of exons and is thought to induce a return to fetal splicing patterns in adult tissues, including the central nervous system (CNS).", "offsetInBeginSection": 111, "offsetInEndSection": 261, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28186082", "text": "This event is synergized with EGF-activated SR proteins to alter alternative splicing of a key small GTPase Rac1 to enhance cell migration, highlighting converging EGF signals on both negative and positive splicing regulators to jointly promote a key cancer pathway.", "offsetInBeginSection": 275, "offsetInEndSection": 425, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/11473790", "text": "lating protein activities in a temporal and spatial manner. The relevance of alternative splicing to diseases of the nervous system is also discussed.", "offsetInBeginSection": 1515, "offsetInEndSection": 1665, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30934641", "text": "We will then proceed to the final and main part of this review, where we will thoroughly comment on the implication of the regulators for Rho GTPases-GEFs (Guanine nucleotide Exchange Factors) and GAPs (GTPase-activating Proteins)-in neurological diseases and disorders.", "offsetInBeginSection": 1126, "offsetInEndSection": 1292, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29671263", "text": "Misregulation of alternative pre-mRNA splicing contributes to various diseases. Understanding how alternative splicing is regulated paves the way to modulating or correcting molecular pathogenesis of the diseases", "offsetInBeginSection": 0, "offsetInEndSection": 212, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29484299", "text": "In this review, we focus on recent progress toward understanding the contributions of alternative splicing to neurogenesis and brain development, which has shed light on how splicing defects may cause brain disorders and diseases.", "offsetInBeginSection": 1206, "offsetInEndSection": 1356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28163190", "text": " Recent studies have demonstrated that RhoGAPs also regulate numerous aspects of neuronal development and are related to various neurodegenerative diseases in GAP-dependent and GAP-independent manners", "offsetInBeginSection": 349, "offsetInEndSection": 549, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17565696", "text": "ssue regulated fashion. The majority of these AS events display differential regulation in central nervous system (CNS) tissues. Approximately half of", "offsetInBeginSection": 561, "offsetInEndSection": 711, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34155820", "text": "We consider recent findings of microexon alternative splicing and their implication for regulating the function of small GTPases in the context of the microglia, and we extrapolate these findings to what is known in neurons.", "offsetInBeginSection": 1052, "offsetInEndSection": 1202, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eeeaaaf36125a426000004", "type": "factoid", "body": "Beremagene Geperpavec is tested for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35347281"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281", "text": "COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDE", "offsetInBeginSection": 311, "offsetInEndSection": 461, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281", "text": "These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.", "offsetInBeginSection": 1378, "offsetInEndSection": 1528, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "64138ce8201352f04a000042", "type": "factoid", "body": "Hairpatches is a single gene mutation associated with what disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19126050", "http://www.ncbi.nlm.nih.gov/pubmed/17141278", "http://www.ncbi.nlm.nih.gov/pubmed/23301070"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301070", "text": "y alopecia. This mutation is a model for the rare human disorder \"glomerulonephritis with sparse hair and telangiectases\" (OMIM 137940). Fine mapping ", "offsetInBeginSection": 200, "offsetInEndSection": 350, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/19126050", "text": "BACKGROUND\nA three-generation Chinese family with Hailey-Hailey disease (HHD) was identified and characterized. The proband developed HHD with severe ", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23301070", "text": "The Hairpatches mouse model allows an investigation into the effects of Tal1, a transcription factor characterized by complex regulation patterns, and its effects on renal disease.", "offsetInBeginSection": 1126, "offsetInEndSection": 1276, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17141278", "text": "lamp technique. A novel mutation, W1191X, was identified in a family with BS. Expression of the WT or the mutant channel (Na(v)1.5/W1191X) co-transfec", "offsetInBeginSection": 626, "offsetInEndSection": 776, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f9cd0b33942b094c000010", "type": "factoid", "body": "What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24307554", "http://www.ncbi.nlm.nih.gov/pubmed/32762877", "http://www.ncbi.nlm.nih.gov/pubmed/33184471", "http://www.ncbi.nlm.nih.gov/pubmed/34731606", "http://www.ncbi.nlm.nih.gov/pubmed/25110022", "http://www.ncbi.nlm.nih.gov/pubmed/34346508"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/34346508", "text": "licing in CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs and to control their splicing in such cells. Diffe", "offsetInBeginSection": 766, "offsetInEndSection": 916, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33184471", "text": "ation. These proteins are involved in neurogenesis and have been associated with various neurological conditions. Here, we analyzed Rbfox2 expression ", "offsetInBeginSection": 71, "offsetInEndSection": 221, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24307554", "text": "PTBP1, and RBFOX2, that contribute to establishing these cell type-specific splicing programs. All of the analyzed data sets are freely available in a", "offsetInBeginSection": 843, "offsetInEndSection": 993, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34731606", "text": "h has a well-established role in alternative splicing, is linked to heart diseases. However, it is unclear whether RBFOX2 has other roles in RNA proce", "offsetInBeginSection": 12, "offsetInEndSection": 162, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32762877", "text": " controls tissue-specific alternative splicing of exons in diverse processes of development. The progenitor cytotrophoblast of the human placenta diff", "offsetInBeginSection": 44, "offsetInEndSection": 194, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32762877", "text": "By studying alternative splicing we further our understanding of placental development, yielding possible insights into preeclampsia, where expression of antiangiogenic isoforms produced through alternative splicing play a critical role in disease development and severity.", "offsetInBeginSection": 1605, "offsetInEndSection": 1755, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25110022", "text": " RNA-binding protein involved in tissue specific alternative splicing regulation and steroid receptors transcriptional activity. Its ability to regula", "offsetInBeginSection": 175, "offsetInEndSection": 325, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f56f7533942b094c000002", "type": "factoid", "body": "Which gene is implicated in Canavan disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17999961", "http://www.ncbi.nlm.nih.gov/pubmed/25647544", "http://www.ncbi.nlm.nih.gov/pubmed/25177395", "http://www.ncbi.nlm.nih.gov/pubmed/23253610", "http://www.ncbi.nlm.nih.gov/pubmed/18978679", "http://www.ncbi.nlm.nih.gov/pubmed/17177147", "http://www.ncbi.nlm.nih.gov/pubmed/24682784", "http://www.ncbi.nlm.nih.gov/pubmed/36267868", "http://www.ncbi.nlm.nih.gov/pubmed/15907664", "http://www.ncbi.nlm.nih.gov/pubmed/22219087"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/25177395", "text": "Canavan disease (MIM 271900) is a rare autosomal recessive leukodystrophy due to mutations in the ASPA gene (MIM 608034) and characterized by a clinical onset at 3-5\u00a0months of life, macrocephaly and poor head control, weak cry and suck, development regression and hypotonia.", "offsetInBeginSection": 25, "offsetInEndSection": 175, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/15907664", "text": "Canavan disease (CD) is an autosomal recessive disorder caused by aspartoacylase (ASPA) gene mutations resulting enzyme deficiency. The homozygous kno", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25647544", "text": "ges. Urine excretion of N-acetylaspartic acid was grossly increased, suggesting Canavan disease. Mutation screening of the ASPA gene confirmed this di", "offsetInBeginSection": 241, "offsetInEndSection": 391, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/22219087", "text": "Linkage analysis was performed by typing three short tandem repeat markers D17S1583 (7.19\u00a0cM), D17S1828 (10.02\u00a0cM) and D17S919 (14.69\u00a0cM) for an already-reported gene/locus ASPA at chromosome 17p13.2 causing Canavan disease.", "offsetInBeginSection": 687, "offsetInEndSection": 837, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/23253610", "text": "Canavan disease is a hereditary leukodystrophy caused by mutations in the aspartoacylase gene (ASPA), leading to loss of enzyme activity and increased concentrations of the substrate N-acetyl-aspartate (NAA) in the brain.", "offsetInBeginSection": 6, "offsetInEndSection": 156, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/18978679", "text": "PURPOSE\nCanavan disease, caused by a deficiency of aspartoacylase, is one of the most common cerebral degenerative diseases of infancy. The aims of th", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24682784", "text": "Canavan disease is a leukodystrophy caused by mutations in the ASPA gene. This gene encodes the enzyme that converts N-acetylaspartate into acetate an", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17999961", "text": " over the world. Canavan disease is caused by a genetic mutation in aspartoacylase gene. We have identified a novel mutation, a homozygous C432+1G>A m", "offsetInBeginSection": 196, "offsetInEndSection": 346, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36267868", "text": "Genetic analysis revealed novel mutations in the aspartoacylase or ASPA gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings.", "offsetInBeginSection": 633, "offsetInEndSection": 783, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17177147", "text": "Canavan disease is a childhood leukodystrophy caused by mutations in the gene for human aspartoacylase ( ASPA), which leads to an abnormal accumulation of the substrate molecule N-acetyl-aspartate (NAA) in the brain.", "offsetInBeginSection": 17, "offsetInEndSection": 167, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6411b4a8201352f04a000035", "type": "yesno", "body": "Is prosopagnosia also known as lack of auditory recognition?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/30625291", "http://www.ncbi.nlm.nih.gov/pubmed/33392335", "http://www.ncbi.nlm.nih.gov/pubmed/9606594", "http://www.ncbi.nlm.nih.gov/pubmed/16767465", "http://www.ncbi.nlm.nih.gov/pubmed/14872395", "http://www.ncbi.nlm.nih.gov/pubmed/29213598", "http://www.ncbi.nlm.nih.gov/pubmed/10957793", "http://www.ncbi.nlm.nih.gov/pubmed/17337129", "http://www.ncbi.nlm.nih.gov/pubmed/8954241"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33392335", "text": "CONCLUSION\nOur case demonstrates that the presentation of prosopagnosia can be atypical, and visual difficulties might be a clinical manifestation solely of prosopagnosia, which emphasizes the importance of routinely considering face recognition impairment among elderly patients with brain lesions.", "offsetInBeginSection": 1404, "offsetInEndSection": 1554, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17337129", "text": "rceptual system seems adequate to allow for recognition, yet recognition cannot take place. Our hypothesis is that a possible cause of associative pro", "offsetInBeginSection": 301, "offsetInEndSection": 451, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/8954241", "text": "ial damage to face recognition units (FRUs). Prosopagnosia without false recognition was seen following near complete destruction of FRUs, but this ty", "offsetInBeginSection": 706, "offsetInEndSection": 856, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/10957793", "text": "odies and rhythms persisted over time. She was also impaired in some aspects of visual recognition including prosopagnosia. To study this patient comp", "offsetInBeginSection": 285, "offsetInEndSection": 435, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30625291", "text": "These results indicate that, in some subjects with developmental prosopagnosia, the face recognition deficit is not an isolated impairment but is associated with deficits in other domains, such as auditory perception.", "offsetInBeginSection": 1363, "offsetInEndSection": 1513, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/14872395", "text": "Agnosia is a neurological recognition deficit that affects a single modality. Visual agnosias include pure object agnosia, prosopagnosia, akinetopsia,", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9606594", "text": "These results provide further evidence that prosopagnosia does not necessarily reflect a general disorder in exemplar recognition, but can be a face-specific deficit.", "offsetInBeginSection": 457, "offsetInEndSection": 607, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/16767465", "text": "Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquire", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29213598", "text": "ve cortex areas, but there is also a congenital form known as developmental prosopagnosia.\n\n\nOBJECTIVES\nTo describe a case of developmental prosopagno", "offsetInBeginSection": 122, "offsetInEndSection": 272, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/17337129", "text": " explained through the concepts of dynamic attractors. Although there is no known cure for prosopagnosia, we believe that the focus of any treatment s", "offsetInBeginSection": 1396, "offsetInEndSection": 1546, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6415babe690f196b5100000d", "type": "summary", "body": "What is telegenetics?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33817891", "http://www.ncbi.nlm.nih.gov/pubmed/35833346", "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "http://www.ncbi.nlm.nih.gov/pubmed/25898928", "http://www.ncbi.nlm.nih.gov/pubmed/34265143", "http://www.ncbi.nlm.nih.gov/pubmed/35464100", "http://www.ncbi.nlm.nih.gov/pubmed/32132456", "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "http://www.ncbi.nlm.nih.gov/pubmed/29362948", "http://www.ncbi.nlm.nih.gov/pubmed/30559758"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35464100", "text": "Telegenetics is the use of telemedicine to deliver clinical genetic services to patients. During the COVID-19 public health emergency (PHE), telegenet", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20406122", "text": "OBJECTIVE\nVideoconferencing for clinical genetics services, or telegenetics, is becoming an increasingly utilized method of delivering genetic counseling to rural areas; however, there has been little qualitative exploration of the practitioner's experience, particularly for hereditary breast/ovarian cancer counseling.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35833346", "text": "DISCUSSION\nOur results suggest that direct-to-patient telegenetics is a satisfactory service delivery model that does not appear to compromise patient-genetic counsellor relationships or increase patient distress.", "offsetInBeginSection": 1994, "offsetInEndSection": 2144, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/32132456", "text": "Telegenetics is a satisfactory solution for both patient and provider and provides benefits for rural patients despite ethical, legal, and reimbursement considerations.", "offsetInBeginSection": 424, "offsetInEndSection": 574, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33817891", "text": "Telegenetics involves the use of technology (generally video conferencing) to remotely provide genetic services. A telegenetics platform is critical f", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30559758", "text": "Telegenetics, the application of telemedicine in the context of genetic services, is a growing market. One of the recent developments in this field is", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25898928", "text": "Telegenetics could be an effective and efficient way of counseling, but its use in Europe is not widely reported, nor is there evidence of international collaboration.", "offsetInBeginSection": 261, "offsetInEndSection": 411, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34265143", "text": "At the University of Pennsylvania (UPenn), a large academic hospital in an urban setting, nearly all genetic counseling (GC) visits for adult-onset disorders within the Department of Neurology were conducted via secure videoconferencing (telegenetics) or telephone between March and December 2020.", "offsetInBeginSection": 241, "offsetInEndSection": 391, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/20411313", "text": "Telegenetics offers an alternative model of delivering genetic counseling to rural and outreach areas; however there is a dearth of qualitative research into the patient's experience.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29362948", "text": "rovided remotely by telephone) and telegenetics (counseling provided remotely using videoconferencing). Little is known about the experience of geneti", "offsetInBeginSection": 185, "offsetInEndSection": 335, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63f04546f36125a426000024", "type": "summary", "body": "What is the mechanism of action of Mitapivat?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/35576529", "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "http://www.ncbi.nlm.nih.gov/pubmed/36260990", "http://www.ncbi.nlm.nih.gov/pubmed/35417638", "http://www.ncbi.nlm.nih.gov/pubmed/34987744", "http://www.ncbi.nlm.nih.gov/pubmed/35988546", "http://www.ncbi.nlm.nih.gov/pubmed/36124781"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "text": "CONCLUSIONS\nThe administration of mitapivat was associated with a rapid increase in the hemoglobin level in 50% of adults with pyruvate kinase deficiency, with a sustained response during a median follow-up of 29 months during the extension phase.", "offsetInBeginSection": 1732, "offsetInEndSection": 1882, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "text": "CONCLUSIONS\nThe administration of mitapivat was associated with a rapid increase in the hemoglobin level in 50% of adults with pyruvate kinase deficiency, with a sustained response during a median follow-up of 29 months during the extension phase.", "offsetInBeginSection": 1756, "offsetInEndSection": 1906, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964", "text": "tic anemia. Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells.\n\n\nMETHODS\nIn this uncontrolled, phase 2 study, ", "offsetInBeginSection": 99, "offsetInEndSection": 249, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781", "text": "XPERT OPINION\nMitapivat is a first-in-class allosteric activator of pyruvate kinase and the first FDA-approved disease directed therapy for PKD. It ha", "offsetInBeginSection": 755, "offsetInEndSection": 905, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546", "text": "BACKGROUND\nMitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36260990", "text": "Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in\u00a0adults with non-transfusion-dependent \u03b1-thalassemia or \u03b2-thalassemia.", "offsetInBeginSection": 13, "offsetInEndSection": 163, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781", "text": "Mitapivat has been shown to offer early and durable improvement in hemoglobin with reduction in transfusion burden, and preliminary data suggest it can induce a negative iron balance in many patients without the use of dedicated iron chelators.", "offsetInBeginSection": 530, "offsetInEndSection": 680, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529", "text": "rved. This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD. This trial was registered at www.clini", "offsetInBeginSection": 1558, "offsetInEndSection": 1708, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638", "text": "In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.", "offsetInBeginSection": 158, "offsetInEndSection": 308, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744", "text": " first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mitapivat has been shown to significantly upregulate both wild", "offsetInBeginSection": 30, "offsetInEndSection": 180, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "641357bc201352f04a000039", "type": "yesno", "body": "Do cells undergoing necroptosis show disruption of their cell membranes?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/31138766", "http://www.ncbi.nlm.nih.gov/pubmed/35365636", "http://www.ncbi.nlm.nih.gov/pubmed/33848465", "http://www.ncbi.nlm.nih.gov/pubmed/30709919", "http://www.ncbi.nlm.nih.gov/pubmed/30449002", "http://www.ncbi.nlm.nih.gov/pubmed/28388403", "http://www.ncbi.nlm.nih.gov/pubmed/30294675", "http://www.ncbi.nlm.nih.gov/pubmed/31640957", "http://www.ncbi.nlm.nih.gov/pubmed/27158445"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/35365636", "text": "Necroptosis is a form of caspase-independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain-like (MLKL) pseudokinase after its activation by the upstream kinases, receptor interacting protein kinase (RIPK)-1 and RIPK3, within a complex known as the necrosome.", "offsetInBeginSection": 53, "offsetInEndSection": 203, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31640957", "text": "Annexin V/PI double staining showed that inhibition of cell apoptosis caused an increase in cell necrosis manifested by such changes as mitochondrial swelling and plasma membrane disruption, as shown by electron microscopy; Hoechst staining showed that the percentage of apoptotic cells was significantly reduced.", "offsetInBeginSection": 1082, "offsetInEndSection": 1232, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33848465", "text": "uring necroptosis. We show that MLKL and phosphoMLKL, key for membrane permeabilization, are exclusively acylated during necroptosis. Reducing the lev", "offsetInBeginSection": 484, "offsetInEndSection": 634, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30709919", "text": "anslocates to and disrupts the plasma membrane, thereby causing necroptotic cell lysis. Herein, we show that activation of necroptosis in mouse dermal", "offsetInBeginSection": 235, "offsetInEndSection": 385, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33848465", "text": "We also show that disruption of endosomal trafficking increases cell viability during necroptosis, possibly by preventing recruitment, or removal, of phosphoMLKL from the plasma membrane.", "offsetInBeginSection": 895, "offsetInEndSection": 1045, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30449002", "text": "Morphological studies using scanning electron microscopy demonstrated disruption of the plasma membrane from cells treated with LyeTx I-b, including the formation of holes or pores.", "offsetInBeginSection": 715, "offsetInEndSection": 895, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/31138766", "text": " exocytosis. Thus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.", "offsetInBeginSection": 664, "offsetInEndSection": 814, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/28388403", "text": "m MLKL-mediated disruption of the cell membrane. In this issue of Cell, Gong et\u00a0al. challenge the notion that MLKL activation is a point of no return ", "offsetInBeginSection": 83, "offsetInEndSection": 233, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27158445", "text": "Finally, based on current evidence, we discuss the potential mechanisms by which the essential, and possibly terminal, necroptotic effector, MLKL, triggers the disruption of cellular membranes to cause cell lysis.", "offsetInBeginSection": 905, "offsetInEndSection": 1055, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/30294675", "text": "loid-like structure that causes cell membrane disruption resulting in cell death. Although the core necroptosis pathway has been elucidated, the detai", "offsetInBeginSection": 622, "offsetInEndSection": 772, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "6414c3f3690f196b51000005", "type": "summary", "body": "What is the definition of dermatillomania?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24091067", "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "http://www.ncbi.nlm.nih.gov/pubmed/25307926", "http://www.ncbi.nlm.nih.gov/pubmed/27286530", "http://www.ncbi.nlm.nih.gov/pubmed/21323095", "http://www.ncbi.nlm.nih.gov/pubmed/29463978"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33654612", "text": "Skin picking disorder, also termed dermatillomania is a condition that leads to repetitive\u00a0picking of their skin ending up in skin and soft tissue damage.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/21323095", "text": "Dermatillomania is a pathologic grooming disorder characterized by repetitive, ritualistic, impulsive skin picking without an underlying dermatologic condition.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/29463978", "text": "Dermatillomania is a rare disease that seldom affects the genitals. Genital dermatillomania has not yet been recognized as a separate entity within th", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24091067", "text": "enticity of which was difficult to confirm. The diagnosis of comorbid factitious disorder with dermatillomania was retained. In view of reducing self-", "offsetInBeginSection": 538, "offsetInEndSection": 688, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/27286530", "text": "At least since the introduction of the official diagnosis Excoriation (Skin-Picking) Disorder in the DSM-5 [1], dermatillomania is an important and growing field of research.", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/25307926", "text": "Dermatillomania is a disorder in which a person habitually picks their skin, and this is a form of self-injury. It can involve any part of the body, b", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}, {"id": "63eeeb70f36125a426000005", "type": "factoid", "body": "What disease can be treated with Glofitamab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/33739857", "http://www.ncbi.nlm.nih.gov/pubmed/34263696", "http://www.ncbi.nlm.nih.gov/pubmed/24286607", "http://www.ncbi.nlm.nih.gov/pubmed/36078155", "http://www.ncbi.nlm.nih.gov/pubmed/34953862", "http://www.ncbi.nlm.nih.gov/pubmed/34941996", "http://www.ncbi.nlm.nih.gov/pubmed/9148449", "http://www.ncbi.nlm.nih.gov/pubmed/35626120"], "snippets": [{"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": " I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab", "offsetInBeginSection": 174, "offsetInEndSection": 324, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "CONCLUSION\nIn patients with predominantly refractory, aggressive B-NHL, glofitamab showed favorable activity with frequent and durable CRs and a predictable and manageable safety profile.", "offsetInBeginSection": 1742, "offsetInEndSection": 1892, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/36078155", "text": "We report two cases of patients with mantle cell lymphoma who relapsed after CAR T therapy and were treated with the bispecific CD20/CD3 T cell engaging antibody glofitamab.", "offsetInBeginSection": 602, "offsetInEndSection": 752, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/9148449", "text": "The effectiveness of topical steroid application in relieving phimosis was studied in 41 boys treated with a potent steroid ointment. 35 patients show", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/33739857", "text": "This trial included heavily pretreated patients with R/R B-NHL; most were refractory to prior therapy (155; 90.6%) and had received a median of three prior therapies.", "offsetInBeginSection": 839, "offsetInEndSection": 989, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34953862", "text": "This is a novel PKPD-based approach for selection of FIH starting dose for a CD20xCD3 bispecific antibody in B-cell lymphoma, evidenced in the glofitamab study, NP30179 (NCT03075696).", "offsetInBeginSection": 1206, "offsetInEndSection": 1356, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34263696", "text": "Glofitamab appears to be a welcome addition to the treatment possibilities for patients with B-cell lymphomas who otherwise have limited therapeutic options.", "offsetInBeginSection": 809, "offsetInEndSection": 959, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/34941996", "text": "30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma. Preclinical studies showed that glofitamab leads to T-cell ", "offsetInBeginSection": 110, "offsetInEndSection": 260, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120", "text": "Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.", "offsetInBeginSection": 1125, "offsetInEndSection": 1275, "beginSection": ["abstract"], "endSection": "abstract"}, {"document": "http://www.ncbi.nlm.nih.gov/pubmed/24286607", "text": "Osteoarthritis is becoming more problematic as the population ages. Recent reports suggest that the benefit of anti-inflammatory drugs is unimpressive", "offsetInBeginSection": 0, "offsetInEndSection": 150, "beginSection": ["abstract"], "endSection": "abstract"}]}]}